

Matrix metalloproteinase inhibitors as therapy for infla

Nature Reviews Drug Discovery

6, 480-498

DOI: [10.1038/nrd2308](https://doi.org/10.1038/nrd2308)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Tumor Necrosis Factor- α Augments Matrix Metalloproteinase-9 Production in Skeletal Muscle Cells through the Activation of Transforming Growth Factor- β -activated Kinase 1 (TAK1)-dependent Signaling Pathway. <i>Journal of Biological Chemistry</i> , 2007, 282, 35113-35124.	1.6	53
2	Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. <i>Trends in Molecular Medicine</i> , 2007, 13, 449-459.	3.5	71
3	Role of proteases in the development and diseases of the lens. <i>Expert Review of Ophthalmology</i> , 2007, 2, 833-844.	0.3	3
4	Targeting MMPs in Acute and Chronic Neurological Conditions. <i>Neurotherapeutics</i> , 2007, 4, 580-589.	2.1	55
5	Insights into the Structure and Domain Flexibility of Full-Length Pro-Matrix Metalloproteinase-9/Gelatinase B. <i>Structure</i> , 2007, 15, 1227-1236.	1.6	113
6	Carbamoylphosphonates part 7. An efficient method for the synthesis of hindered carbamoylphosphonates using 4-nitrophenoxycarbonylphosphonate diesters. <i>Tetrahedron Letters</i> , 2008, 49, 2875-2877.	0.7	6
7	Mediterranean diet and cardioprotection: Wild artichoke inhibits metalloproteinase 9. <i>Molecular Nutrition and Food Research</i> , 2008, 52, 1147-1152.	1.5	10
8	A Macrophage Cell Model for Selective Metalloproteinase Inhibitor Design. <i>ChemBioChem</i> , 2008, 9, 2087-2095.	1.3	11
9	Role of the hemopexin domain of matrix metalloproteinases in cell migration. <i>Journal of Cellular Physiology</i> , 2008, 217, 643-651.	2.0	127
10	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 8745-8759.	1.4	37
11	Specific targeting of metzincin family members with small-molecule inhibitors: Progress toward a multifarious challenge. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 8781-8794.	1.4	90
12	Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3333-3337.	1.0	18
13	Gingival crevicular fluid and serum matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 levels in renal transplant patients undergoing different immunosuppressive therapy. <i>Journal of Clinical Periodontology</i> , 2008, 35, 221-229.	2.3	10
14	A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice. <i>British Journal of Pharmacology</i> , 2008, 155, 714-721.	2.7	17
15	Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. <i>Immunology</i> , 2008, 124, 42-50.	2.0	64
16	Drug discovery in the extracellular matrix. <i>Drug Discovery Today</i> , 2008, 13, 685-694.	3.2	37
17	The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2781-2789.	1.6	43
18	Expression and regulation of matrix metalloproteinase-12 in experimental autoimmune encephalomyelitis and by bone marrow derived macrophages <i>in vitro</i> . <i>Journal of Neuroimmunology</i> , 2008, 199, 24-34.	1.1	39

#	ARTICLE	IF	CITATIONS
19	Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis. <i>Reproductive Toxicology</i> , 2008, 25, 442-446.	1.3	43
20	Nanoimprint lithography based fabrication of shape-specific, enzymatically-triggered smart nanoparticles. <i>Journal of Controlled Release</i> , 2008, 125, 263-272.	4.8	218
21	Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis. <i>Arthritis Research and Therapy</i> , 2008, 10, 229.	1.6	34
22	Progress in matrix metalloproteinase research. <i>Molecular Aspects of Medicine</i> , 2008, 29, 290-308.	2.7	593
23	Synthetic active site-directed inhibitors of metzincins: Achievement and perspectives. <i>Molecular Aspects of Medicine</i> , 2008, 29, 329-338.	2.7	40
24	Atherosclerosis, COPD and chronic inflammation. <i>Respiratory Medicine: COPD Update</i> , 2008, 4, 60-65.	0.3	8
25	Carbamoylphosphonate Matrix Metalloproteinase Inhibitors 6: <i>cis</i> -2-Aminocyclohexylcarbamoylphosphonic Acid, A Novel Orally Active Antimetastatic Matrix Metalloproteinase-2 Selective Inhibitor—Synthesis and Pharmacodynamic and Pharmacokinetic Analysis. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1406-1414.	2.9	42
26	Matrix metalloproteinase inhibitors as anticancer agents. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 1156-1168.	1.2	67
27	Frontrunners in novel pharmacotherapy of COPD. <i>Current Opinion in Pharmacology</i> , 2008, 8, 300-307.	1.7	46
28	Neuroimmunology of central nervous system viral infections: the cells, molecules and mechanisms involved. <i>Current Opinion in Pharmacology</i> , 2008, 8, 472-479.	1.7	47
29	Keratinocyte Expression of MMP3 Enhances Differentiation and Prevents Tumor Establishment. <i>American Journal of Pathology</i> , 2008, 173, 1528-1539.	1.9	48
30	Breaching the basement membrane: who, when and how?. <i>Trends in Cell Biology</i> , 2008, 18, 560-574.	3.6	387
31	The reduction of platinum(IV) and palladium(IV) ions by 2,6-pyridinedihydroxamic acid. <i>Dalton Transactions</i> , 2008, , 6933.	1.6	10
32	Identification of MMP-12 Inhibitors by Using Biosensor-Based Screening of a Fragment Library. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3449-3459.	2.9	53
33	Protease-Specific Nanosensors for Magnetic Resonance Imaging. <i>Bioconjugate Chemistry</i> , 2008, 19, 2440-2445.	1.8	55
34	Protease Inhibitors for the Potential Treatment of Chronic Obstructive Pulmonary Disease and Asthma. <i>Annual Reports in Medicinal Chemistry</i> , 2008, , 171-185.	0.5	3
35	Serum or Plasma Samples?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 611-614.	1.1	84
36	Matrix Metalloproteinases and Their Tissue Inhibitors (TIMPs) in <i>Plasmodium falciparum</i> Malaria: Serum Levels of TIMP-1 Are Associated with Disease Severity. <i>Journal of Infectious Diseases</i> , 2008, 197, 1614-1620.	1.9	50

#	ARTICLE	IF	CITATIONS
37	MMP-12 Catalytic Domain Recognizes Triple Helical Peptide Models of Collagen V with Exosites and High Activity. <i>Journal of Biological Chemistry</i> , 2008, 283, 21779-21788.	1.6	39
38	Emerging Pharmacotherapies for COPD. <i>Chest</i> , 2008, 134, 1278-1286.	0.4	105
39	Treg Depletionâ€“enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus. <i>Molecular Therapy</i> , 2008, 16, 1217-1226.	3.7	47
40	Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2008, 11, 81.	0.9	525
41	MMP19 Is Essential for T Cell Development and T Cell-Mediated Cutaneous Immune Responses. <i>PLoS ONE</i> , 2008, 3, e2343.	1.1	51
42	The emerging roles of ADAMTS-7 and ADAMTS-12 matrix metalloproteinases. <i>Open Access Rheumatology: Research and Reviews</i> , 2009, 1, 121.	0.8	10
43	Matrix Metalloproteinases as Drug Targets in Infections Caused by Gram-Negative Bacteria and in Septic Shock. <i>Clinical Microbiology Reviews</i> , 2009, 22, 224-239.	5.7	129
44	Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy. <i>Pharmacological Reviews</i> , 2009, 61, 198-223.	7.1	436
45	Inhibition of Enzymatic Degradation of Adhesive-Dentin Interfaces. <i>Journal of Dental Research</i> , 2009, 88, 1101-1106.	2.5	206
46	Plasma Matrix Metalloproteinases in Neonates Having Surgery for Congenital Heart Disease. <i>Heart International</i> , 2009, 4, hi.2009.e4.	0.4	1
47	ADAMTS-7 Mediates Vascular Smooth Muscle Cell Migration and Neointima Formation in Balloon-Injured Rat Arteries. <i>Circulation Research</i> , 2009, 104, 688-698.	2.0	189
48	Acute and Chronic Inflammation Induces Disease Pathogenesis. , 2009, , 25-40.		3
49	Plasma and Brain Matrix Metalloproteinase-9 After Acute Focal Cerebral Ischemia in Rats. <i>Stroke</i> , 2009, 40, 2836-2842.	1.0	121
50	Neuroinflammation and Neuroprotective Strategies in Acute Ischaemic Stroke - from bench to bedside. <i>Current Molecular Medicine</i> , 2009, 9, 336-354.	0.6	49
51	Contributions of multiple proteases to neurotoxicity in a mouse model of intracerebral haemorrhage. <i>Brain</i> , 2009, 132, 26-36.	3.7	58
52	Gene Deletion of the Kinin Receptor B1 Attenuates Cardiac Inflammation and Fibrosis During the Development of Experimental Diabetic Cardiomyopathy. <i>Diabetes</i> , 2009, 58, 1373-1381.	0.3	102
53	Matrix Metalloproteinase Inhibitors (MMPIs) from Marine Natural Products: the Current Situation and Future Prospects. <i>Marine Drugs</i> , 2009, 7, 71-84.	2.2	58
54	Metalloproteinase MT5-MMP is an essential modulator of neuro-immune interactions in thermal pain stimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 16451-16456.	3.3	69

#	ARTICLE	IF	CITATIONS
55	Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. <i>Human Molecular Genetics</i> , 2009, 18, 2584-2598.	1.4	141
56	The Rap80-BRCC36 de-ubiquitinating enzyme complex antagonizes RNF8-Ubc13-dependent ubiquitination events at DNA double strand breaks. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3166-3171.	3.3	196
57	Attacking the multi-tiered proteolytic pathology of COPD: New insights from basic and translational studies. , 2009, 121, 132-146.		44
58	Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. <i>Toxicology and Applied Pharmacology</i> , 2009, 237, 69-82.	1.3	58
59	Matrix metalloproteinase proteomics: substrates, targets, and therapy. <i>Current Opinion in Cell Biology</i> , 2009, 21, 645-653.	2.6	239
60	Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. <i>Lancet Neurology</i> , The, 2009, 8, 205-216.	4.9	515
61	Reverse degradomics, monitoring of proteolytic trimming by multi- and confocal detection of fluorescent substrates and reaction products. <i>Electrophoresis</i> , 2009, 30, 2366-2377.	1.3	13
62	Including receptor flexibility and induced fit effects into the design of MMP inhibitors. <i>Journal of Molecular Recognition</i> , 2010, 23, 173-182.	1.1	29
63	The dual role of thymidine phosphorylase in cancer development and chemotherapy. <i>Medicinal Research Reviews</i> , 2009, 29, 903-953.	5.0	166
64	Inhibition of Matrix Metalloproteinases Enhances In Vitro Repair of the Meniscus. <i>Clinical Orthopaedics and Related Research</i> , 2009, 467, 1557-1567.	0.7	66
65	Increased serum levels of matrix metalloproteinase-9 in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2009, 90, 248-252.	0.7	4
66	Increased cyclooxygenase activity impairs apoptosis of inflammatory neutrophils in mice lacking gelatinase B/matrix metalloproteinase-9. <i>Immunology</i> , 2009, 128, e262-74.	2.0	8
67	Poly(ADP-Ribose) Polymerase Mediates Inflammation in a Mouse Model of Contact Hypersensitivity. <i>Journal of Investigative Dermatology</i> , 2009, 129, 234-238.	0.3	18
68	Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation. <i>Nature Chemical Biology</i> , 2009, 5, 628-630.	3.9	97
69	Matrix metalloproteinase-9 expression and release from skin fibroblasts interacting with keratinocytes: Upregulation in response to sulphur mustard. <i>Toxicology</i> , 2009, 263, 26-31.	2.0	43
70	3,4-Disubstituted benzofuran P1 MMP-13 inhibitors: Optimization of selectivity and reduction of protein binding. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4546-4550.	1.0	10
71	Metalloproteinases and their inhibitors diagnostic and therapeutic opportunities in orthopedics. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2009, 80, 693-703.	1.2	105
72	Different circulating metalloproteinases profiles in women with migraine with and without aura. <i>Clinica Chimica Acta</i> , 2009, 408, 60-64.	0.5	38

#	ARTICLE	IF	CITATIONS
73	Matrix metalloprotease regulation of neuropathic pain. Trends in Pharmacological Sciences, 2009, 30, 336-340.	4.0	151
74	Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience, 2009, 158, 983-994.	1.1	468
75	Matrix metalloproteinase 12 silencing: A therapeutic approach to treat pathological lung tissue remodeling?. Pulmonary Pharmacology and Therapeutics, 2009, 22, 267-278.	1.1	41
76	Cloning and expression of ADAM-related metalloproteases in equine laminitis. Veterinary Immunology and Immunopathology, 2009, 129, 231-241.	0.5	49
77	Identification of an Orally Efficacious Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Asthma. Journal of Medicinal Chemistry, 2009, 52, 5408-5419.	2.9	32
78	Fluorinated Inhibitors of Matrix Metalloproteinases. , 0, , 99-115.		0
79	New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy. Expert Opinion on Drug Delivery, 2009, 6, 793-811.	2.4	23
80	Future Therapies. , 2009, , 737-749.		0
82	Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13. Journal of Medicinal Chemistry, 2009, 52, 3523-3538.	2.9	52
83	Matrix Metalloproteinase-12 Deficiency Worsens Relapsing-Remitting Experimental Autoimmune Encephalomyelitis in Association with Cytokine and Chemokine Dysregulation. American Journal of Pathology, 2009, 174, 898-909.	1.9	42
84	Novel mechanisms and new therapies for chronic obstructive pulmonary disease. Therapy: Open Access in Clinical Medicine, 2009, 6, 795-804.	0.2	1
85	Effects of Novel Semiselective Matrix Metalloproteinase Inhibitors on Ex Vivo Cardiac Structure-Function. Journal of Cardiovascular Pharmacology, 2009, 53, 452-461.	0.8	5
86	Mechanisms of Metal-Dependent Hydrolases in Metabolism. , 2010, , 547-581.		14
87	Anti-Inflammatory Activity of Chitin, Chitosan and Their Derivatives. , 2010, , 215-221.		2
89	Phosphorus based inhibitors of matrix metalloproteinases. Comptes Rendus Chimie, 2010, 13, 1191-1202.	0.2	16
90	On-line chromatographic screening of matrix metalloproteinase inhibitors using immobilized MMP-9 enzyme reactor. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 1777-1783.	1.2	14
91	Minocycline with aspirin: a therapeutic approach in the treatment of diabetic neuropathy. Neurological Sciences, 2010, 31, 705-716.	0.9	28
92	Modulation of Brain Injury as a Target of Adjunctive Therapy in Bacterial Meningitis. Current Infectious Disease Reports, 2010, 12, 266-273.	1.3	16

#	ARTICLE	IF	CITATIONS
93	Structural and functional bases for allosteric control of MMP activities: Can it pave the path for selective inhibition?. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 29-38.	1.9	119
94	Matrix metalloproteinases: Evolution, gene regulation and functional analysis in mouse models. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 3-19.	1.9	444
95	To bind zinc or not to bind zinc: An examination of innovative approaches to improved metalloproteinase inhibition. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 72-94.	1.9	250
96	Matrix metalloproteinases: What do they not do? New substrates and biological roles identified by murine models and proteomics. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 39-54.	1.9	449
97	Involvement of matrix metalloproteinase-3 in CCL5/CCR5 pathway of chondrosarcomas metastasis. <i>Biochemical Pharmacology</i> , 2010, 79, 209-217.	2.0	53
98	Nuclear-targeted inhibition of NF- κ B on MMP-9 production by N-2-(4-bromophenyl) ethyl caffeamide in human monocytic cells. <i>Chemico-Biological Interactions</i> , 2010, 184, 403-412.	1.7	63
99	Matrix Metalloproteinase-9 Promotes Chronic Lymphocytic Leukemia B Cell Survival through Its Hemopexin Domain. <i>Cancer Cell</i> , 2010, 17, 160-172.	7.7	138
100	Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor. <i>Virology</i> , 2010, 397, 130-138.	1.1	116
101	Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3. <i>Experimental Cell Research</i> , 2010, 316, 836-847.	1.2	22
102	IL-6 and high glucose synergistically upregulate MMP-1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and c-Jun. <i>Journal of Cellular Biochemistry</i> , 2010, 110, 248-259.	1.2	38
103	A combined molecular modeling study on gelatinases and their potent inhibitors. <i>Journal of Computational Chemistry</i> , 2010, 31, 24-42.	1.5	18
105	Effects of detergents on catalytic activity of human endometase/matrixlysin 2, a putative cancer biomarker. <i>Analytical Biochemistry</i> , 2010, 396, 262-268.	1.1	25
106	SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5039-5043.	1.0	31
107	Aminoalkylcarbamoylphosphonates reduce TNF α release from activated immune cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6518-6523.	1.0	7
108	Optimization of total protein and activity assays for the detection of MMP-12 in induced human sputum. <i>BMC Pulmonary Medicine</i> , 2010, 10, 40.	0.8	9
109	Enzymatic degradation of adhesive dentin interfaces produced by mild self-etch adhesives. <i>European Journal of Oral Sciences</i> , 2010, 118, 494-501.	0.7	89
110	Fell-Muir Lecture: Metalloproteinases: from demolition squad to master regulators. <i>International Journal of Experimental Pathology</i> , 2010, 91, 303-313.	0.6	24
111	Emerging principles in protease-based drug discovery. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 690-701.	21.5	476

#	ARTICLE	IF	CITATIONS
112	The impact of the extracellular matrix on inflammation. <i>Nature Reviews Immunology</i> , 2010, 10, 712-723.	10.6	780
114	Bioresponsive nanosensors in medical imaging. <i>Journal of the Royal Society Interface</i> , 2010, 7, S83-91.	1.5	17
115	Novel Application of Proton Pump Inhibitor for the Prevention of Colitis-Induced Colorectal Carcinogenesis beyond Acid Suppression. <i>Cancer Prevention Research</i> , 2010, 3, 963-974.	0.7	41
116	New Therapies for Chronic Obstructive Pulmonary Disease. <i>Medical Principles and Practice</i> , 2010, 19, 330-338.	1.1	69
117	Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2). <i>Biochemical Journal</i> , 2010, 430, 79-86.	1.7	34
118	Relationship Between Leukocyte Kinetics and Behavioral Tests Changes in the Inflammatory Process of Hemorrhagic Stroke Recovery. <i>International Journal of Neuroscience</i> , 2010, 120, 765-773.	0.8	17
119	Applications of Chitin and Its Derivatives in Biological Medicine. <i>International Journal of Molecular Sciences</i> , 2010, 11, 5152-5164.	1.8	311
120	Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, G323-G334.	1.6	116
121	Human Rhinovirus Infection Up-Regulates MMP-9 Production in Airway Epithelial Cells via NF- κ B. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2010, 43, 201-209.	1.4	56
122	Recent Advances in the Development of MMPis and APNis Based on the Pyrrolidine Platforms. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010, 10, 794-805.	1.1	39
123	Matrix Metalloproteinases. <i>Current Medicinal Chemistry</i> , 2010, 17, 3751-3768.	1.2	194
124	Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2010, 45, 351-423.	2.3	263
125	Measurement of Urinary Total Desmosine and Isodesmosine Using Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2010, 82, 3745-3750.	3.2	35
126	Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the S1 ϵ^2 cavity. <i>Biochimie</i> , 2010, 92, 1501-1508.	1.3	88
127	Small molecules for bone diseases. <i>Expert Opinion on Therapeutic Patents</i> , 2010, 20, 563-582.	2.4	4
128	Matrix Metalloproteinase Inhibitor Batimastat Alleviates Pathology and Improves Skeletal Muscle Function in Dystrophin-Deficient mdx Mice. <i>American Journal of Pathology</i> , 2010, 177, 248-260.	1.9	71
129	New drugs and targets for asthma and COPD. <i>Progress in Respiratory Research</i> , 2010, , 3-23.	0.1	5
130	Mouse Models of MMP and TIMP Function. <i>Methods in Molecular Biology</i> , 2010, 622, 31-52.	0.4	30

#	ARTICLE	IF	CITATIONS
131	Enhancing QM/MM Molecular Dynamics Sampling in Explicit Environments via an Orthogonal-Space-Random-Walk-Based Strategy. <i>Journal of Physical Chemistry B</i> , 2011, 115, 3924-3935.	1.2	20
132	Matrix metalloproteinase inhibitor properties of tetracyclines: Therapeutic potential in cardiovascular diseases. <i>Pharmacological Research</i> , 2011, 64, 551-560.	3.1	80
133	Bacterial meningitis: current therapy and possible future treatment options. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 1053-1065.	2.0	20
134	Selective Water-Soluble Gelatinase Inhibitor Prodrugs. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6676-6690.	2.9	44
135	Probing cytokines, chemokines and matrix metalloproteinases towards better immunotherapies of multiple sclerosis. <i>Cytokine and Growth Factor Reviews</i> , 2011, 22, 359-365.	3.2	33
136	Bloodâ€“Brain Barrier Breakdown in Acute and Chronic Cerebrovascular Disease. <i>Stroke</i> , 2011, 42, 3323-3328.	1.0	620
137	Tissue factor pathway inhibitor-2 is downregulated by ox-LDL and inhibits ox-LDL induced vascular smooth muscle cells proliferation and migration. <i>Thrombosis Research</i> , 2011, 128, 179-185.	0.8	30
138	Potent â€œClickedâ€“MMP2 Inhibitors: Synthesis, Molecular Modeling and Biological Exploration. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 4587.	1.5	29
139	Matrix Metalloproteinase-9 and Haemozoin: Wedding Rings for Human Host and <i>Plasmodium falciparum</i> Parasite in Complicated Malaria. <i>Journal of Tropical Medicine</i> , 2011, 2011, 1-11.	0.6	35
140	Insights into the Complex Formed by Matrix Metalloproteinase-2 and Alloxan Inhibitors: Molecular Dynamics Simulations and Free Energy Calculations. <i>PLoS ONE</i> , 2011, 6, e25597.	1.1	12
141	Simvastatin in traumatic brain injury: Effect on brain edema mechanisms. <i>Critical Care Medicine</i> , 2011, 39, 2300-2307.	0.4	49
142	Natural haemozoin modulates matrix metalloproteinases and induces morphological changes in human microvascular endothelium. <i>Cellular Microbiology</i> , 2011, 13, 1275-1285.	1.1	42
143	Increased matrix metalloproteinase activity is associated with migraine and migraine-related metabolic dysfunctions. <i>European Journal of Neurology</i> , 2011, 18, 571-576.	1.7	38
144	Inhibitor of PI3K ^{Î³} ameliorates TNBSâ€“induced colitis in mice by affecting the functional activity of CD4 + CD25 + FoxP3 + regulatory T cells. <i>British Journal of Pharmacology</i> , 2011, 163, 358-374.	2.7	37
145	Regulation of matrix metalloproteinase activity in health and disease. <i>FEBS Journal</i> , 2011, 278, 28-45.	2.2	313
146	Pyreneâ€“Based Inhibitors of Metalloproteinase Types 2 and 3 May Work as Conformationâ€“Selective Inhibitors. <i>Chemical Biology and Drug Design</i> , 2011, 78, 191-198.	1.5	23
147	Crucial role of HSP90 in the Akt-dependent promotion of angiogenic-like effect of glucose-regulated protein94 (Grp94)-IgG complexes. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 2768-2780.	1.6	4
148	Altered matrix metalloproteinases and tissue inhibitors of metalloproteinases in embryos from diabetic rats during early organogenesis. <i>Reproductive Toxicology</i> , 2011, 32, 449-462.	1.3	14

#	ARTICLE	IF	CITATIONS
149	Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. <i>Drug Discovery Today</i> , 2011, 16, 762-78.	3.2	88
150	Tuberculosis Immunopathology: The Neglected Role of Extracellular Matrix Destruction. <i>Science Translational Medicine</i> , 2011, 3, 71ps6.	5.8	100
151	Matrix metalloproteinases in tumorigenesis: an evolving paradigm. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 3853-3868.	2.4	234
152	Extracellular proteolysis in macrophage migration: Losing grip for a breakthrough. <i>European Journal of Immunology</i> , 2011, 41, 2805-2813.	1.6	80
153	Synthesis of Oxacycles Employing the Oxa ϵ Pictet α Spengler Reaction: Recent Developments and New Prospects. <i>European Journal of Organic Chemistry</i> , 2011, 2011, 5195-5231.	1.2	95
154	Orally Active, Antimetastatic, Nontoxic Diphenyl Ether α Derived Carbamoylphosphonate Matrix Metalloproteinase Inhibitors. <i>ChemMedChem</i> , 2011, 6, 1471-1477.	1.6	12
155	Selective non zinc binding inhibitors of MMP13. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4215-4219.	1.0	20
156	POVME: An algorithm for measuring binding-pocket volumes. <i>Journal of Molecular Graphics and Modelling</i> , 2011, 29, 773-776.	1.3	186
157	Multiple Roles of Metalloproteinases in Neurological Disorders. <i>Progress in Molecular Biology and Translational Science</i> , 2011, 99, 241-263.	0.9	45
158	Role of Metalloproteinases in Rotator Cuff Tear. <i>Sports Medicine and Arthroscopy Review</i> , 2011, 19, 207-212.	1.0	42
159	Neu1 Sialidase and Matrix Metalloproteinase-9 Cross-talk Is Essential for Toll-like Receptor Activation and Cellular Signaling. <i>Journal of Biological Chemistry</i> , 2011, 286, 36532-36549.	1.6	75
160	Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice. <i>Human Molecular Genetics</i> , 2011, 20, 4345-4359.	1.4	63
161	Minocycline with Aspirin: An Approach to Attenuate Diabetic Nephropathy in Rats. <i>Renal Failure</i> , 2011, 33, 72-78.	0.8	17
162	Mobilization of Bone Marrow Cells by CSF3 Protects Mice from Bleomycin-Induced Lung Injury. <i>Respiration</i> , 2011, 82, 358-368.	1.2	14
163	Lung Cancer in Pulmonary Fibrosis: Tales of Epithelial Cell Plasticity. <i>Respiration</i> , 2011, 81, 353-358.	1.2	46
164	Osteopontin-Stimulated Expression of Matrix Metalloproteinase-9 Causes Cardiomyopathy in the mdx Model of Duchenne Muscular Dystrophy. <i>Journal of Immunology</i> , 2011, 187, 2723-2731.	0.4	57
165	Concentration Kinetics of Serum MMP-9 and TIMP-1 after Blunt Multiple Injuries in the Early Posttraumatic Period. <i>Mediators of Inflammation</i> , 2012, 2012, 1-8.	1.4	13
166	Altered Circulating Levels of Matrix Metalloproteinases and Inhibitors Associated with Elevated Type 2 Cytokines in Lymphatic Filariasis. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1681.	1.3	15

#	ARTICLE	IF	CITATIONS
167	MMP-2 Selectivity in Hydroxamate-Type Inhibitors. <i>Current Medicinal Chemistry</i> , 2012, 19, 1036-1064.	1.2	31
168	Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia. <i>Oncolmmunology</i> , 2012, 1, 618-629.	2.1	21
169	The role of manganese superoxide dismutase in skin aging. <i>Dermato-Endocrinology</i> , 2012, 4, 232-235.	1.9	56
170	Potential of aspirin-induced cerebroprotection by minocycline: A therapeutic approach to attenuate exacerbation of transient focal cerebral ischaemia. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 25-34.	0.9	17
171	Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction. <i>International Journal of Impotence Research</i> , 2012, 24, 38-43.	1.0	12
172	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. <i>Cell Cycle</i> , 2012, 11, 4447-4461.	1.3	22
173	Neural Functions of Matrix Metalloproteinases: Plasticity, Neurogenesis, and Disease. <i>Biochemistry Research International</i> , 2012, 2012, 1-8.	1.5	69
174	Matrix Metalloproteinases in Neuropathic Pain and Migraine: Friends, Enemies, and Therapeutic Targets. <i>Pain Research and Treatment</i> , 2012, 2012, 1-10.	1.7	48
175	Regulation of the basement membrane by epithelia generated forces. <i>Physical Biology</i> , 2012, 9, 065003.	0.8	18
176	Upregulated Expression of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinases in BALB/c Mouse Brain Challenged with Japanese Encephalitis Virus. <i>NeuroImmunoModulation</i> , 2012, 19, 241-254.	0.9	15
177	Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2012, 15, 555-570.	0.6	18
178	Peptide-Based Selective Inhibitors of Matrix Metalloproteinase-Mediated Activities. <i>Molecules</i> , 2012, 17, 14230-14248.	1.7	53
179	New and Paradoxical Roles of Matrix Metalloproteinases in the Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 2012, 3, 140.	1.6	88
180	Role of matrix metalloproteinases 2 and 9 in ex vivo Trypanosoma cruzi infection of human placental chorionic villi. <i>Placenta</i> , 2012, 33, 991-997.	0.7	21
181	Hydroxamic Acids as Matrix Metalloproteinase Inhibitors. <i>Exs</i> , 2012, 103, 137-176.	1.4	20
182	The Gelatinases and Their Inhibitors: The Structure-Activity Relationships. <i>Exs</i> , 2012, , 57-82.	1.4	3
183	Ultrasound Enhanced Matrix Metalloproteinase-9 Triggered Release of Contents from Echogenic Liposomes. <i>Molecular Pharmaceutics</i> , 2012, 9, 2554-2564.	2.3	32
184	Carbamoylphosphonates Control Tumor Cell Proliferation and Dissemination by Simultaneously Inhibiting Carbonic Anhydrase IX and Matrix Metalloproteinase-2. Toward Nontoxic Chemotherapy Targeting Tumor Microenvironment. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7875-7882.	2.9	23

#	ARTICLE	IF	CITATIONS
185	Target-Activated Prodrugs (TAPs) for the Autoregulated Inhibition of MMP12. ACS Medicinal Chemistry Letters, 2012, 3, 653-657.	1.3	4
186	Chemical Biology for Understanding Matrix Metalloproteinase Function. ChemBioChem, 2012, 13, 2002-2020.	1.3	46
187	Human matrix metalloproteinases: An ubiquitarian class of enzymes involved in several pathological processes. Molecular Aspects of Medicine, 2012, 33, 119-208.	2.7	194
188	Metalloproteases and rotator cuff disease. Journal of Shoulder and Elbow Surgery, 2012, 21, 200-208.	1.2	99
189	Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. Biochemical and Biophysical Research Communications, 2012, 423, 1-5.	1.0	38
190	Neurological Diseases in Relation to the Blood-Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1139-1151.	2.4	347
191	Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF- α converting enzyme (TACE/ADAM-17). Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 533-540.	2.5	8
192	Probing the Binding Affinity and Proteolytic Stability of Trifluoromethyl Peptide Mimics as Protease Inhibitors. Molecular Medicine and Medicinal, 2012, , 63-90.	0.4	0
193	From molecular cardiology to emergency medical practice: the role of inflammatory markers. American Journal of Emergency Medicine, 2012, 30, 1210-1211.	0.7	4
194	N-O-Isopropyl sulfonamido-based hydroxamates: Kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors. Biochemical Pharmacology, 2012, 84, 813-820.	2.0	13
195	Targeting mutant huntingtin for the development of disease-modifying therapy. Drug Discovery Today, 2012, 17, 1217-1223.	3.2	16
196	Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9. European Journal of Medicinal Chemistry, 2012, 58, 368-376.	2.6	42
197	A therapeutic approach to treat cardiovascular dysfunction of diabetes. Experimental and Toxicologic Pathology, 2012, 64, 847-853.	2.1	10
198	Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy. Journal of Ocular Biology, Diseases, and Informatics, 2012, 5, 1-8.	0.2	34
199	Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opinion on Investigational Drugs, 2012, 21, 797-805.	1.9	140
200	VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood, 2012, 120, 4653-4662.	0.6	275
201	Modeling Structural Coordination and Ligand Binding in Zinc Proteins with a Polarizable Potential. Journal of Chemical Theory and Computation, 2012, 8, 1314-1324.	2.3	100
202	Regulation of Matrix Metalloproteinases 2 and 9 Activities by Peroxynitrites in Term Placentas From Type 2 Diabetic Patients. Reproductive Sciences, 2012, 19, 814-822.	1.1	18

#	ARTICLE	IF	CITATIONS
203	DIDS Prevents Ischemic Membrane Degradation in Cultured Hippocampal Neurons by Inhibiting Matrix Metalloproteinase Release. PLoS ONE, 2012, 7, e43995.	1.1	10
204	Bone Marrow-Derived Matrix Metalloproteinase-9 Is Associated with Fibrous Adhesion Formation after Murine Flexor Tendon Injury. PLoS ONE, 2012, 7, e40602.	1.1	37
205	PEGylation Extends Circulation Half-Life While Preserving In Vitro and In Vivo Activity of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1). PLoS ONE, 2012, 7, e50028.	1.1	39
206	Pharmacomodulation of Broad Spectrum Matrix Metalloproteinase Inhibitors Towards Regulation of Gelatinases. , 2012, , .		1
207	Matrix Metalloproteinase-10 (MMP-10) Interaction with Tissue Inhibitors of Metalloproteinases TIMP-1 and TIMP-2. Journal of Biological Chemistry, 2012, 287, 15935-15946.	1.6	88
208	Contribution of matrix metalloproteinase 2 to joint destruction in group B <i>Streptococcus</i> -induced murine arthritis. Arthritis and Rheumatism, 2012, 64, 1089-1097.	6.7	22
209	Free Energy Calculations on Snake Venom Metalloproteinase BaP1. Chemical Biology and Drug Design, 2012, 79, 990-1000.	1.5	5
210	Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. , 2012, 133, 257-279.		98
211	Dietary treatments enriched in olive and safflower oils regulate seric and placental matrix metalloproteinases in maternal diabetes. Placenta, 2012, 33, 8-16.	0.7	27
212	Administration, distribution, metabolism and elimination of polymer therapeutics. Journal of Controlled Release, 2012, 161, 446-460.	4.8	262
213	Matrix metalloproteinase inhibition therapy for vascular diseases. Vascular Pharmacology, 2012, 56, 232-244.	1.0	146
214	Tetracyclines and pain. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 225-241.	1.4	34
215	Selection and Finding of Lead Peptides Dual-targeting MMP14 and Metal Ions by Subtractive Cell Surface Panning and Molecular Docking. International Journal of Peptide Research and Therapeutics, 2012, 18, 31-40.	0.9	3
216	Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase-2. Biochemical Pharmacology, 2013, 86, 469-475.	2.0	12
217	Inhibitors of Hydrolyzing Metalloenzymes. , 2013, , 565-598.		1
218	Hydroxamic Acids: An Important Class of Metalloenzyme Inhibitors. , 2013, , 683-708.		7
219	Matrix metalloproteinases (MMPs) inhibitory effects of an octameric oligopeptide isolated from abalone <i>Haliotis discus hannai</i> . Food Chemistry, 2013, 141, 503-509.	4.2	32
220	Secreted proteases of <i>Trypanosoma brucei gambiense</i> : Possible targets for sleeping sickness control?. BioFactors, 2013, 39, 407-414.	2.6	15

#	ARTICLE	IF	CITATIONS
221	Minocycline suppresses experimental autoimmune encephalomyelitis by increasing tissue inhibitors of metalloproteinases. <i>Neuropathology</i> , 2013, 33, 612-620.	0.7	25
222	Monocyte-derived dendritic cell subpopulations use different types of matrix metalloproteinases inhibited by GM6001. <i>Immunobiology</i> , 2013, 218, 1361-1369.	0.8	19
223	Wasting mechanisms in muscular dystrophy. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 2266-2279.	1.2	115
224	A Matrix Metalloproteinase 1â€‘Cleavable Composite Peptide Derived From Transforming Growth Factor Î²â€‘Inducible Gene h3 Potently Inhibits Collagenâ€‘Induced Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1753-1763.	6.7	35
225	The efficient expression of human fibroblast collagenase in <i>Escherichia coli</i> and the discovery of flavonoid inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2013, 28, 741-746.	2.5	8
226	The Concise Guide to <sc>PHARMACOLOGY</sc> 2013/14: Enzymes. <i>British Journal of Pharmacology</i> , 2013, 170, 1797-1867.	2.7	416
227	Matrix metalloproteinases 2 and 9 as diagnostic markers in the progression to Chagas cardiomyopathy. <i>American Heart Journal</i> , 2013, 165, 558-566.	1.2	44
228	Efficient soluble expression of secreted matrix metalloproteinase 26 in <i>Brevibacillus choshinensis</i> . <i>Protein Expression and Purification</i> , 2013, 91, 125-133.	0.6	8
229	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. <i>Advances in Biological Regulation</i> , 2013, 53, 146-155.	1.4	14
230	Hydantoin based inhibitors of MMP13â€‘Discovery of AZD6605. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4705-4712.	1.0	20
231	A disintegrin and metalloproteinase-12 (ADAM12): Function, roles in disease progression, and clinical implications. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 4445-4455.	1.1	51
232	Zymography methods for visualizing hydrolytic enzymes. <i>Nature Methods</i> , 2013, 10, 211-220.	9.0	271
233	Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. <i>Nature Neuroscience</i> , 2013, 16, 273-280.	7.1	1,121
234	Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 233-242.	4.0	282
235	Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2013, 48, 222-272.	2.3	622
236	Overcoming neuriteâ€‘inhibitory chondroitin sulfate proteoglycans in the astrocyte matrix. <i>Glia</i> , 2013, 61, 972-984.	2.5	75
237	Unraveling Hidden Regulatory Sites in Structurally Homologous Metalloproteases. <i>Journal of Molecular Biology</i> , 2013, 425, 2330-2346.	2.0	52
238	Sulphonamides: Deserving class as MMP inhibitors?. <i>European Journal of Medicinal Chemistry</i> , 2013, 60, 89-100.	2.6	58

#	ARTICLE	IF	CITATIONS
239	Trachoma: Protective and Pathogenic Ocular Immune Responses to Chlamydia trachomatis. PLoS Neglected Tropical Diseases, 2013, 7, e2020.	1.3	111
240	Vascular Extracellular Matrix in Atherosclerosis. Cardiology in Review, 2013, 21, 270-288.	0.6	96
241	Matrix Metalloproteinases 2 and 9 Are Differentially Expressed in Patients with Indeterminate and Cardiac Clinical Forms of Chagas Disease. Infection and Immunity, 2013, 81, 3600-3608.	1.0	48
242	Intracellular Regulation of Matrix Metalloproteinase-2 Activity: New Strategies in Treatment and Protection of Heart Subjected to Oxidative Stress. Scientifica, 2013, 2013, 1-12.	0.6	22
243	Evaluating Prodrug Strategies for Esterase-Triggered Release of Alcohols. ChemMedChem, 2013, 8, 1662-1667.	1.6	20
244	Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy. Clinical and Experimental Immunology, 2013, 173, 131-139.	1.1	57
245	Incorporation of Bulky and Cationic Cyclam-Triazole Moieties into Marimastat Can Generate Potent MMP Inhibitory Activity without Inducing Cytotoxicity. ChemistryOpen, 2013, 2, 99-105.	0.9	12
246	Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins. Current Drug Targets, 2013, 14, 287-324.	1.0	32
247	The Anti-inflammatory Role of Endometase/Matrilysin-2 in Human Prostate Cancer Cells. Journal of Cancer, 2013, 4, 296-303.	1.2	5
248	Mechanisms of Metal-Dependent Hydrolases in Metabolism. , 2013, , .		0
249	ADAMTS7. , 2013, , 1180-1186.		0
250	Compromised NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Chronic SIV/SHIV Infection. PLoS ONE, 2013, 8, e56309.	1.1	11
251	The Role of Microglia and Matrix Metalloproteinases Involvement in Neuroinflammation and Gliomas. Clinical and Developmental Immunology, 2013, 2013, 1-15.	3.3	147
252	Metalloproteases and tendinopathy. Muscles, Ligaments and Tendons Journal, 2013, 3, 51-7.	0.1	56
253	Gliomas Biology: Angiogenesis and Invasion. , 2013, , .		2
254	Evaluation of 11 Scoring Functions Performance on Matrix Metalloproteinases. International Journal of Medicinal Chemistry, 2014, 2014, 1-9.	2.2	10
255	Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer's disease: evidence for a pro-amyloidogenic role of MT1-MMP. Frontiers in Aging Neuroscience, 2014, 6, 247.	1.7	60
256	Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models. Frontiers in Cellular Neuroscience, 2014, 8, 30.	1.8	70

#	ARTICLE	IF	CITATIONS
257	Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF- α Release from Activated Microglia and TNF- α Converting Enzyme Activity. <i>Biomolecules and Therapeutics</i> , 2014, 22, 414-419.	1.1	17
258	On the Structure and functions of gelatinase B/Matrix metalloproteinase-9 in neuroinflammation. <i>Progress in Brain Research</i> , 2014, 214, 193-206.	0.9	54
259	Endogenous and synthetic MMP inhibitors in CNS physiopathology. <i>Progress in Brain Research</i> , 2014, 214, 313-351.	0.9	39
260	Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression. <i>Cancers</i> , 2014, 6, 240-296.	1.7	154
261	Secreted Frizzled-related protein 2 as a target in antifibrotic therapeutic intervention. <i>American Journal of Physiology - Cell Physiology</i> , 2014, 306, C531-C539.	2.1	51
262	A Novel Chemically Modified Curcumin Reduces Severity of Experimental Periodontal Disease in Rats: Initial Observations. <i>Mediators of Inflammation</i> , 2014, 2014, 1-10.	1.4	50
263	The Role of Matrix Metalloproteinases in Colorectal Cancer. <i>Cancers</i> , 2014, 6, 366-375.	1.7	185
264	Metalloproteinase-9 and neutrophil gelatinase-associated lipocalin plasma and tissue levels evaluation in middle cerebral artery aneurysms. <i>British Journal of Neurosurgery</i> , 2014, , 1-5.	0.4	24
265	<i>In Silico</i> Study Combining Docking and QSAR Methods on a Series of Matrix Metalloproteinase 13 Inhibitors. <i>Archiv Der Pharmazie</i> , 2014, 347, 825-833.	2.1	9
266	Heterogeneity of serum gelatinases <i>MMP-2</i> and <i>MMP-9</i> isoforms and charge variants. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 242-252.	1.6	28
267	Matrix metalloproteinase (<i>MMP-2</i>) and <i>MMP-9</i> as inflammation markers of <i>Trichinella spiralis</i> and <i>Trichinella pseudospiralis</i> infections in mice. <i>Parasite Immunology</i> , 2014, 36, 540-549.	0.7	21
268	Preparation and evaluation of the effect of Fe ₃ O ₄ @piroctone olamine magnetic nanoparticles on matrix metalloproteinase-2: A preliminary in vitro study. <i>Biotechnology and Applied Biochemistry</i> , 2014, 61, 676-682.	1.4	8
269	Infliximab Restores the Dysfunctional Matrix Remodeling Protein and Growth Factor Gene Expression in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 339-352.	0.9	36
270	What Does the Future Hold for the Therapy of COPD?. <i>Milestones in Drug Therapy</i> , 2014, , 129-146.	0.1	1
271	Inhibition of Neutrophil Collagenase/MMP-8 and Gelatinase B/MMP-9 and Protection against Endotoxin Shock. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	0.9	6
272	Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin. <i>Targeted Oncology</i> , 2014, 9, 251-261.	1.7	11
273	The biology of <i>NK</i> cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (<i>HCT</i>). <i>Immunological Reviews</i> , 2014, 258, 45-63.	2.8	83
274	Host matrix metalloproteinases in cerebral malaria: new kids on the block against blood-brain barrier integrity?. <i>Fluids and Barriers of the CNS</i> , 2014, 11, 1.	2.4	63

#	ARTICLE	IF	CITATIONS
275	Matrix metalloproteinase 9 opposes diet-induced muscle insulin resistance in mice. <i>Diabetologia</i> , 2014, 57, 603-613.	2.9	36
276	Nitric oxide-matrix metalloproteinase-9 interactions: Biological and pharmacological significance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 603-617.	1.9	79
277	Design, synthesis and preliminary evaluation of L [±] -sulfonyl L ³ -(glyciny- amino)proline peptidomimetics as matrix metalloproteinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 3055-3064.	1.4	18
278	Is there new hope for therapeutic matrix metalloproteinase inhibition?. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 904-927.	21.5	631
279	Design, synthesis, evaluation and 3D-QSAR analysis of benzosulfonamide benzenesulfonates as potent and selective inhibitors of MMP-2. <i>RSC Advances</i> , 2014, 4, 39214.	1.7	13
280	Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 338-348.	4.0	127
281	Functional links between gelatinase B/matrix metalloproteinase-9 and prominin-1/CD133 in diabetic retinal vasculopathy and neuropathy. <i>Progress in Retinal and Eye Research</i> , 2014, 43, 76-91.	7.3	19
282	Matrix metalloproteinase inhibitors: a patent review (2011 – 2013). <i>Expert Opinion on Therapeutic Patents</i> , 2014, 24, 1039-1052.	2.4	26
283	FRET-based and other fluorescent proteinase probes. <i>Biotechnology Journal</i> , 2014, 9, 266-281.	1.8	46
284	Enhancement of Matrix Metalloproteinase 2 and 9 Inhibitory Action of Minocycline by Aspirin: An Approach to Attenuate Outcome of Acute Myocardial Infarction in Diabetes. <i>Archives of Medical Research</i> , 2014, 45, 203-209.	1.5	20
285	Towards a safe and effective chlamydial vaccine: Lessons from the eye. <i>Vaccine</i> , 2014, 32, 1572-1578.	1.7	53
286	Protective role of bortezomib in steatotic liver ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression. <i>Transplant Immunology</i> , 2014, 30, 93-98.	0.6	28
287	Emerging targets in neuroinflammation-driven chronic pain. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 533-548.	21.5	754
288	Blood-Brain Barrier and Cerebral Malaria: The Road So Far. <i>Journal of Bacteriology & Parasitology</i> , 2014, 05, .	0.2	1
289	The Role of the Macrophage in the Development of Aortic Dissection. <i>Cardiology</i> , 2014, 127, 121-122.	0.6	1
290	A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions. <i>Scientific Reports</i> , 2015, 5, 18277.	1.6	58
294	Nonproteolytic functions of matrix metalloproteinases in pathology and insights for the development of novel therapeutic inhibitors. <i>Metalloproteinases in Medicine</i> , 0, , 19.	1.0	15
295	Hyperglycemia-Induced Modulation of the Physiognomy and Angiogenic Potential of Fibroblasts Mediated by Matrix Metalloproteinase-2: Implications for Venous Stenosis Formation Associated with Hemodialysis Vascular Access in Diabetic Milieu. <i>Journal of Vascular Research</i> , 2015, 52, 334-346.	0.6	7

#	ARTICLE	IF	CITATIONS
296	Multifaceted role of matrix metalloproteinases (MMPs). <i>Frontiers in Molecular Biosciences</i> , 2015, 2, 19.	1.6	149
297	Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0127063.	1.1	150
298	Adult Vascular Wall Resident Multipotent Vascular Stem Cells, Matrix Metalloproteinases, and Arterial Aneurysms. <i>Stem Cells International</i> , 2015, 2015, 1-16.	1.2	14
299	Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. <i>Mediators of Inflammation</i> , 2015, 2015, 1-27.	1.4	154
300	The Function and Roles of ADAMTS-7 in Inflammatory Diseases. <i>Mediators of Inflammation</i> , 2015, 2015, 1-11.	1.4	15
301	Matrix Metalloproteinases in Inflammatory Bowel Disease: An Update. <i>Mediators of Inflammation</i> , 2015, 2015, 1-19.	1.4	109
302	Immobilized Enzyme Reactor Chromatography for Online Gelatinase Inhibitors Screening. <i>Chromatographia</i> , 2015, 78, 763-773.	0.7	3
303	Matrix Metalloproteinase-9 Is Essential for Physiological Beta Cell Function and Islet Vascularization in Adult Mice. <i>American Journal of Pathology</i> , 2015, 185, 1094-1103.	1.9	20
304	Nitro-based selective inhibitors against matrix metalloproteinase-7 over matrix metalloproteinase-1. <i>RSC Advances</i> , 2015, 5, 104725-104732.	1.7	2
305	Ligand-induced expansion of the S1 site in the anthrax toxin lethal factor. <i>FEBS Letters</i> , 2015, 589, 3836-3841.	1.3	4
306	Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas. <i>Genes and Diseases</i> , 2015, 2, 26-34.	1.5	393
307	Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study. <i>Molecular BioSystems</i> , 2015, 11, 1041-1051.	2.9	32
308	New strategies for targeting matrix metalloproteinases. <i>Matrix Biology</i> , 2015, 44-46, 239-246.	1.5	89
309	Spinal cord injury induced neuropathic pain: Molecular targets and therapeutic approaches. <i>Metabolic Brain Disease</i> , 2015, 30, 645-658.	1.4	14
310	Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1. <i>Biochemical Journal</i> , 2015, 465, 259-270.	1.7	39
311	Cardiosome mediated regulation of MMP-9 in diabetic heart: role of mir29b and mir455 in exercise. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 2153-2161.	1.6	154
312	Matrix Metalloproteinase 9 (MMP-9). , 2015, , 237-259.		1
313	Hydrophilic extract from <i>Posidonia oceanica</i> inhibits activity and expression of gelatinases and prevents HT1080 human fibrosarcoma cell line invasion. <i>Cell Adhesion and Migration</i> , 2015, 9, 422-431.	1.1	23

#	ARTICLE	IF	CITATIONS
314	ADAMTS-7 promotes vascular smooth muscle cells proliferation in vitro and in vivo. <i>Science China Life Sciences</i> , 2015, 58, 674-681.	2.3	18
315	Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 355, 410-428.	1.3	65
316	Identification of matrix metalloproteinase inhibitors by chemical arrays. <i>Bioscience, Biotechnology and Biochemistry</i> , 2015, 79, 1597-1602.	0.6	7
317	Drugging the schistosome zinc-dependent HDACs: current progress and future perspectives. <i>Future Medicinal Chemistry</i> , 2015, 7, 783-800.	1.1	22
318	Matrix metalloproteinase inhibitors prevent sepsis-induced refractoriness to vasoconstrictors in the cecal ligation and puncture model in rats. <i>European Journal of Pharmacology</i> , 2015, 765, 164-170.	1.7	12
319	Preclinical assessment of 2-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. <i>Immunopharmacology and Immunotoxicology</i> , 2015, 37, 535-540.	1.1	48
320	Grafting MAP peptide to dental polymer inhibits MMP-8 activity. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2015, 103, 324-331.	1.6	6
321	A QSAR study on the inhibition mechanism of matrix metalloproteinase-12 by arylsulfone analogs based on molecular orbital calculations. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 793-806.	1.5	21
322	A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [18F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 192-202.	1.4	17
323	The role of matrix metalloproteinases and neutrophil gelatinase-associated lipocalin in central and peripheral arterial aneurysms. <i>Surgery</i> , 2015, 157, 155-162.	1.0	44
324	Evaluation of remodeling process in small-diameter cell-free tissue-engineered arterial graft. <i>Journal of Vascular Surgery</i> , 2015, 62, 734-743.	0.6	52
325	Evidence for a Proapoptotic Role of Matrix Metalloproteinase-26 in Human Prostate Cancer Cells and Tissues. <i>Journal of Cancer</i> , 2016, 7, 80-87.	1.2	14
326	Elevated Matrix Metalloproteinase in Aqueous Humor in Patients with Open-Angle Glaucoma. <i>Journal of Korean Ophthalmological Society</i> , 2016, 57, 601.	0.0	1
327	Changes in Oxidative Stress and Inflammatory Biomarkers in Fragile Adults over Fifty Years of Age and in Elderly People Exclusively Fed Enteral Nutrition. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 1-11.	1.9	3
328	ADAM17 Inhibitors Attenuate Corneal Epithelial Detachment Induced by Mustard Exposure. , 2016, 57, 1687.		15
329	Author Response: Causal Management of Keratoconus: Controlling Inflammation. , 2016, 57, 2165.		1
330	Seaweed Application in Cosmetics. , 2016, , 423-441.		29
331	Endothelial Response to Glucocorticoids in Inflammatory Diseases. <i>Frontiers in Immunology</i> , 2016, 7, 592.	2.2	76

#	ARTICLE	IF	CITATIONS
332	Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1768.	1.8	17
333	Synthesis, Antiphospholipase A2, Antiprotease, Antibacterial Evaluation and Molecular Docking Analysis of Certain Novel Hydrazones. <i>Molecules</i> , 2016, 21, 1664.	1.7	11
334	The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis. <i>PLoS ONE</i> , 2016, 11, e0158653.	1.1	7
335	The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2016, 51, 295-358.	2.3	62
336	Mechanistic investigations of matrix metalloproteinase-8 inhibition by metal abstraction peptide. <i>Biointerphases</i> , 2016, 11, 021006.	0.6	1
337	Role of metabolic modulator Bet-CA in altering mitochondrial hyperpolarization to suppress cancer associated angiogenesis and metastasis. <i>Scientific Reports</i> , 2016, 6, 23552.	1.6	5
338	sFRP2 activates Wnt/ β -catenin signaling in cardiac fibroblasts: differential roles in cell growth, energy metabolism, and extracellular matrix remodeling. <i>American Journal of Physiology - Cell Physiology</i> , 2016, 311, C710-C719.	2.1	71
339	Matrix Metalloproteinases. , 2016, , 621-629.		3
340	Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 14970-14975.	3.3	72
341	Glycosylation of matrix metalloproteases and tissue inhibitors: present state, challenges and opportunities. <i>Biochemical Journal</i> , 2016, 473, 1471-1482.	1.7	49
342	Inhibition of MMP-9-dependent Degradation of Gelatin, but Not Other MMP-9 Substrates, by the MMP-9 Hemopexin Domain Blades 1 and 4. <i>Journal of Biological Chemistry</i> , 2016, 291, 11751-11760.	1.6	22
343	Intracellular Wnt/Beta-Catenin Signaling Underlying 17beta-Estradiol-Induced Matrix Metalloproteinase 9 Expression in Human Endometriosis1. <i>Biology of Reproduction</i> , 2016, 94, 70.	1.2	27
344	AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity. <i>Diabetes</i> , 2016, 65, 2295-2310.	0.3	132
345	Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis. <i>Bioscience Reports</i> , 2016, 36, .	1.1	143
346	Cognitive dysfunction in Duchenne muscular dystrophy: a possible role for neuromodulatory immune molecules. <i>Journal of Neurophysiology</i> , 2016, 116, 1304-1315.	0.9	36
347	Microbiomic and Posttranslational Modifications as Preludes to Autoimmune Diseases. <i>Trends in Molecular Medicine</i> , 2016, 22, 746-757.	3.5	52
348	Synthesis and in Vitro and in Vivo Evaluation of MMP-12 Selective Optical Probes. <i>Bioconjugate Chemistry</i> , 2016, 27, 2407-2417.	1.8	26
349	Neutralization of MMP-2 protects <i>Staphylococcus aureus</i> infection induced septic arthritis in mice and regulates the levels of cytokines. <i>Microbial Pathogenesis</i> , 2016, 99, 148-161.	1.3	13

#	ARTICLE	IF	CITATIONS
350	MT1-MMP and its potential role in the vertebrate intestinal morphogenesis. <i>Acta Histochemica</i> , 2016, 118, 729-735.	0.9	9
351	Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13. <i>ChemMedChem</i> , 2016, 11, 1892-1898.	1.6	16
352	Cicatrizaci3n y ayudas biol3gicas en las reparaciones del manguito de los rotadores. Revisi3n de conceptos actuales. <i>Revista Colombiana De Ortopedia Y TraumatologÃa</i> , 2016, 30, 26-35.	0.0	0
353	Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier. <i>Science Translational Medicine</i> , 2016, 8, 364ra152.	5.8	94
354	Metalloproteinases and their inhibitors are influenced by inhalative glucocorticoid therapy in combination with environmental dust reduction in equine recurrent airway obstruction. <i>BMC Veterinary Research</i> , 2016, 12, 282.	0.7	16
355	Prospects for the therapeutic application of sulfated polysaccharides of brown algae in diseases of the cardiovascular system: review. <i>Pharmaceutical Biology</i> , 2016, 54, 3126-3135.	1.3	50
356	Genetic Deletion of Tissue Inhibitor of Metalloproteinase-1/TIMP-1 Alters Inflammation and Attenuates Fibrosis in Dextran Sodium Sulphate-induced Murine Models of Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1336-1350.	0.6	34
357	Cloning, expression, purification, and characterization of the catalytic domain of sika deer MMP-13. <i>Protein Expression and Purification</i> , 2016, 127, 16-21.	0.6	4
358	Trivalent metal ions based on inorganic compounds with in vitro inhibitory activity of matrix metalloproteinase 13. <i>Enzyme and Microbial Technology</i> , 2016, 92, 9-17.	1.6	5
359	Bone biology-related gingival transcriptome in ageing and periodontitis in non-human primates. <i>Journal of Clinical Periodontology</i> , 2016, 43, 408-417.	2.3	26
360	Self-Assembled Wound Dressings Silence MMP-9 and Improve Diabetic Wound Healing In Vivo. <i>Advanced Materials</i> , 2016, 28, 1809-1817.	11.1	174
361	Emerging Evidence for Pathogenesis of Sporadic Cerebral Small Vessel Disease. <i>Stroke</i> , 2016, 47, 554-560.	1.0	120
362	Ion-Current-Based Temporal Proteomic Profiling of Influenza-A-Virus-Infected Mouse Lungs Revealed Underlying Mechanisms of Altered Integrity of the Lung Microvascular Barrier. <i>Journal of Proteome Research</i> , 2016, 15, 540-553.	1.8	11
363	Matrix Metalloproteinase 1 Causes Vasoconstriction and Enhances Vessel Reactivity to Angiotensin II via Protease-Activated Receptor 1. <i>Reproductive Sciences</i> , 2016, 23, 542-548.	1.1	36
364	Salusin-Î2 Promotes Vascular Smooth Muscle Cell Migration and Intimal Hyperplasia After Vascular Injury via ROS/NF-ÎB/MMP-9 Pathway. <i>Antioxidants and Redox Signaling</i> , 2016, 24, 1045-1057.	2.5	94
365	Role of Matrix Metalloproteinases in the Pathogenesis of Traumatic Brain Injury. <i>Molecular Neurobiology</i> , 2016, 53, 6106-6123.	1.9	70
366	Small molecules with anti-inflammatory properties in clinical development. , 2016, 157, 163-187.		45
367	Thrombin/Matrix Metalloproteinase-9-Dependent SK-N-SH Cell Migration is Mediated Through a PLC/PKC/MAPKs/NF-ÎB Cascade. <i>Molecular Neurobiology</i> , 2016, 53, 5833-5846.	1.9	10

#	ARTICLE	IF	CITATIONS
368	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 438-448.	1.9	79
369	From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases. <i>International Wound Journal</i> , 2017, 14, 233-240.	1.3	36
370	Interplay of extracellular matrix and leukocytes in lung inflammation. <i>Cellular Immunology</i> , 2017, 312, 1-14.	1.4	89
371	Hemorrhagic metalloproteinase, Cc HSMâ€œII, isolated from <i>Cerastes cerastes</i> venom: Purification and biochemical characterization. <i>Journal of Biochemical and Molecular Toxicology</i> , 2017, 31, N/A.	1.4	7
372	Pro-Inflammatory and Pro-Fibrogenic Effects of Ionic and Particulate Arsenide and Indium-Containing Semiconductor Materials in the Murine Lung. <i>ACS Nano</i> , 2017, 11, 1869-1883.	7.3	19
373	Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview. <i>European Journal of Medicinal Chemistry</i> , 2017, 129, 72-109.	2.6	55
374	Spatial mismatch, non-additive binding energies and selectivity in supramolecular complexes. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 2146-2151.	1.5	7
375	Monitoring proteolytic processing events by quantitative mass spectrometry. <i>Expert Review of Proteomics</i> , 2017, 14, 409-418.	1.3	10
376	Clove extract and eugenol suppress inflammatory responses elicited by <i>Propionibacterium acnes</i> in vitro and in vivo. <i>Food and Agricultural Immunology</i> , 2017, 28, 916-931.	0.7	25
377	Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4496-4502.	2.9	6
378	Matrix metalloproteinase collagenolysis in health and disease. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 1940-1951.	1.9	151
379	Biochemical and Biological Attributes of Matrix Metalloproteinases. <i>Progress in Molecular Biology and Translational Science</i> , 2017, 147, 1-73.	0.9	784
380	Synergic and antagonistic relationship between MMP-2 and MMP-9 with fibrosis and inflammation in Chagas' cardiomyopathy. <i>Parasite Immunology</i> , 2017, 39, e12446.	0.7	26
381	Towards integrating extracellular matrix and immunological pathways. <i>Cytokine</i> , 2017, 98, 79-86.	1.4	54
382	Effects of <i>Nigella sativa</i> Extract on Markers of Cerebral Angiogenesis after Global Ischemia of Brain in Rats. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 1514-1520.	0.7	9
383	Computational Approaches to Matrix Metalloprotease Drug Design. <i>Methods in Molecular Biology</i> , 2017, 1579, 273-285.	0.4	2
384	Zincâ€œMetalloproteinase Inhibitors: Evaluation of the Complex Role Played by the Zinc-Binding Group on Potency and Selectivity. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 403-414.	2.9	27
385	A DNA-directed covalent conjugation fluorescence probe for in vitro detection of functional matrix metalloproteinases. <i>Analyst</i> , 2017, 142, 634-640.	1.7	12

#	ARTICLE	IF	CITATIONS
386	Pyridazinone: an attractive lead for anti-inflammatory and analgesic drug discovery. <i>Future Medicinal Chemistry</i> , 2017, 9, 95-127.	1.1	32
387	Understanding Chemico-Biological Interactions of Glutamate MMP-2 Inhibitors through Rigorous Alignment-Dependent 3D-QSAR Analyses. <i>ChemistrySelect</i> , 2017, 2, 7888-7898.	0.7	12
388	Design and discovery of novel thiazole derivatives as potential MMP inhibitors to protect against acute lung injury in sepsis rats via attenuation of inflammation and apoptotic oxidative stress. <i>RSC Advances</i> , 2017, 7, 32909-32922.	1.7	10
389	Integrative studies implicate matrix metalloproteinase-12 as a culprit gene for large artery atherosclerotic stroke. <i>Journal of Internal Medicine</i> , 2017, 282, 429-444.	2.7	34
390	A new gallium complex inhibits tumor cell invasion and matrix metalloproteinase MMP-14 expression and activity. <i>Metallomics</i> , 2017, 9, 1176-1184.	1.0	10
391	In vitro studies on nobiletin isolated from citrus plants and the bioactive metabolites, inhibitory action against gelatinase enzymatic activity and the molecular mechanisms in human retinal Müller cell line. <i>Biomedicine and Pharmacotherapy</i> , 2017, 93, 70-80.	2.5	11
392	Endotoxemia shifts neutrophils with TIMP-free gelatinase B/MMP-9 from bone marrow to the periphery and induces systematic upregulation of TIMP-1. <i>Haematologica</i> , 2017, 102, 1671-1682.	1.7	13
393	Spine-on-a-chip: Human annulus fibrosus degeneration model for simulating the severity of intervertebral disc degeneration. <i>Biomicrofluidics</i> , 2017, 11, 064107.	1.2	14
394	Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease. <i>Progress in Molecular Biology and Translational Science</i> , 2017, 147, 267-299.	0.9	47
395	Chemokine isoforms and processing in inflammation and immunity. <i>Journal of Autoimmunity</i> , 2017, 85, 45-57.	3.0	67
396	Pro-oxidant/pro-inflammatory alterations in the offspring's heart of mild diabetic rats are regulated by maternal treatments with a mitochondrial antioxidant. <i>Reproductive Toxicology</i> , 2017, 73, 269-279.	1.3	10
397	The multifaceted role of metalloproteinases in physiological and pathological conditions in embryonic and adult brains. <i>Progress in Neurobiology</i> , 2017, 155, 36-56.	2.8	34
398	Challenges to develop novel anti-inflammatory and analgesic drugs. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1427.	3.3	21
399	Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 125-135.	0.6	126
400	Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. <i>Progress in Molecular Biology and Translational Science</i> , 2017, 148, 355-420.	0.9	101
401	Regulation of Matrix Metalloproteinase in the Pathogenesis of Diabetic Retinopathy. <i>Progress in Molecular Biology and Translational Science</i> , 2017, 148, 67-85.	0.9	56
402	dCas9-mediated transcriptional activation of tissue inhibitor of metalloproteinases. <i>Matrix Metalloproteinases in Medicine</i> , 2017, Volume 4, 63-73.	1.0	6
403	Effect of subcutaneous treatment with human umbilical cord blood-derived multipotent stem cells on peripheral neuropathic pain in rats. <i>Korean Journal of Physiology and Pharmacology</i> , 2017, 21, 153.	0.6	12

#	ARTICLE	IF	CITATIONS
404	MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study. <i>BioMed Research International</i> , 2017, 2017, 1-12.	0.9	13
405	Sulfonyl phosphonic 1,4-dithia-7-azaspiro[4,4]nonane derivatives as matrix metalloproteinase inhibitors: Synthesis, a docking study, and biological evaluation. <i>Drug Discoveries and Therapeutics</i> , 2017, 11, 118-125.	0.6	2
406	Differential Expression of Matrix Metalloproteinases 2, 9 and Cytokines by Neutrophils and Monocytes in the Clinical Forms of Chagas Disease. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005284.	1.3	40
407	Regulation of intestinal permeability: The role of proteases. <i>World Journal of Gastroenterology</i> , 2017, 23, 2106.	1.4	124
409	Immunomodulation as Rescue for Chronic Atonic Skin Wounds. <i>Trends in Immunology</i> , 2018, 39, 341-354.	2.9	33
410	Biomolecular basis of matrix metallo proteinase-9 activity. <i>Future Medicinal Chemistry</i> , 2018, 10, 1093-1112.	1.1	19
411	Nesfatin-1 promotes VSMC migration and neointimal hyperplasia by upregulating matrix metalloproteinases and downregulating PPAR β . <i>Biomedicine and Pharmacotherapy</i> , 2018, 102, 711-717.	2.5	26
412	Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. <i>Advances in Pharmacology</i> , 2018, 81, 241-330.	1.2	373
413	Wound healing in the eye: Therapeutic prospects. <i>Advanced Drug Delivery Reviews</i> , 2018, 126, 162-176.	6.6	53
414	Matrix Metalloproteinases. , 2018, , 3005-3013.		0
415	An integrated structure- and pharmacophore-based MMP-12 virtual screening. <i>Molecular Diversity</i> , 2018, 22, 383-395.	2.1	9
416	Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2018, 40, 156-165.e5.	1.1	31
417	Multiple molecular modelling studies on some derivatives and analogues of glutamic acid as matrix metalloproteinase-2 inhibitors. <i>SAR and QSAR in Environmental Research</i> , 2018, 29, 43-68.	1.0	15
418	Association of serum ADAMTS-7 levels with left ventricular reverse remodeling after ST-elevation myocardial infarction. <i>European Journal of Medical Research</i> , 2018, 23, 15.	0.9	2
419	Salvianolic acid A attenuates ischemia reperfusion induced rat brain damage by protecting the blood brain barrier through MMP-9 inhibition and anti-inflammation. <i>Chinese Journal of Natural Medicines</i> , 2018, 16, 184-193.	0.7	41
420	Matrix metalloproteinases in emphysema. <i>Matrix Biology</i> , 2018, 73, 34-51.	1.5	79
421	Natural antioxidant polyphenols on inflammation management: Anti-glycation activity vs metalloproteinases inhibition. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 893-904.	5.4	96
422	Low molecular mass natural and synthetic inhibitors of snake venom metalloproteinases. <i>Toxin Reviews</i> , 2018, 37, 19-26.	1.5	12

#	ARTICLE	IF	CITATIONS
423	Neutrophils: a cornerstone of liver ischemia and reperfusion injury. <i>Laboratory Investigation</i> , 2018, 98, 51-62.	1.7	133
424	Simultaneous Inhibition of Tumor Necrosis Factor Receptor 1 and Matrix Metalloproteinase 8 Completely Protects Against Acute Inflammation and Sepsis. <i>Critical Care Medicine</i> , 2018, 46, e67-e75.	0.4	12
425	Utility of Glycosylated TIMP3 molecules: Inhibition of MMPs and TACE to improve cardiac function in rat myocardial infarct model. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00442.	1.1	17
426	Gelatinase B/Matrix Metalloproteinase-9 as Innate Immune Effector Molecule in Achalasia. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e208.	1.3	16
427	Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF- κ B Phosphorylation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4084.	1.8	32
428	New <i>in Vivo</i> Compatible Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitors. <i>Bioconjugate Chemistry</i> , 2018, 29, 3715-3725.	1.8	15
429	Gelatinase B/matrix metalloproteinase-9 is a phase-specific effector molecule, independent from Fas, in experimental autoimmune encephalomyelitis. <i>PLoS ONE</i> , 2018, 13, e0197944.	1.1	11
430	Metalloproteinases in non-alcoholic fatty liver disease and their behavior in liver fibrosis. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2018, 41, .	0.3	5
431	Comparisons of gut microbiota profiles in wild-type and gelatinase B/matrix metalloproteinase-9-deficient mice in acute DSS-induced colitis. <i>Npj Biofilms and Microbiomes</i> , 2018, 4, 18.	2.9	10
432	Matrix metalloproteinase 9 (MMP9) in wound healing of diabetic foot ulcer: Molecular target and structure-based drug design. <i>Wound Medicine</i> , 2018, 22, 1-13.	2.7	33
433	Microbial production of novel sulphated alkaloids for drug discovery. <i>Scientific Reports</i> , 2018, 8, 7980.	1.6	44
434	LC-MS analysis to determine the biodistribution of a polymer coated ilomastat ocular implant. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 157, 100-106.	1.4	2
436	Metal-ligand interactions in drug design. <i>Nature Reviews Chemistry</i> , 2018, 2, 100-112.	13.8	124
437	Effects of Vitamin D3 on the NADPH Oxidase and Matrix Metalloproteinase 9 in an Animal Model of Global Cerebral Ischemia. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-14.	1.9	32
438	Association of serum ADAMTS7 levels and genetic variant rs1994016 with acute coronary syndrome in a Chinese population: A case control study. <i>Atherosclerosis</i> , 2018, 275, 312-318.	0.4	5
439	The effect of Coenzyme Q10 supplementation on serum levels of lactate, pyruvate, matrix metalloproteinase 9 and nitric oxide in women with migraine. A double blind, placebo, controlled randomized clinical trial. <i>European Journal of Integrative Medicine</i> , 2018, 21, 70-76.	0.8	9
440	The <i>in vitro</i> antioxidant properties of <i>Muscari comosum</i> bulbs and their inhibitory activity on enzymes involved in inflammation, post-prandial hyperglycemia, and cognitive/neuromuscular functions. <i>Journal of Food Biochemistry</i> , 2018, 42, e12580.	1.2	8
441	4-Thiazolidinone Derivatives as MMP Inhibitors in Tissue Damage: Synthesis, Biological Evaluation and Docking Studies. <i>Molecules</i> , 2018, 23, 415.	1.7	9

#	ARTICLE	IF	CITATIONS
442	Novel Arginine-containing Macrocyclic MMP Inhibitors: Synthesis, 99mTc-labeling, and Evaluation. <i>Scientific Reports</i> , 2018, 8, 11647.	1.6	9
443	Triumph and tumult of matrix metalloproteinases and their crosstalk with eicosanoids in cancer. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 279-288.	2.7	7
444	A New Perspective in Utilizing MMP-9 as a Therapeutic Target for Alzheimer's Disease and Type 2 Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1-16.	1.2	36
445	Design, Synthesis, and Biological Evaluation of Tetrahydrocarbolone Derivatives as Selective Subnanomolar Gelatinase Inhibitors. <i>ChemMedChem</i> , 2018, 13, 1343-1352.	1.6	4
446	The ectoenzyme-side of matrix metalloproteinases (MMPs) makes inflammation by serum amyloid A (SAA) and chemokines go round. <i>Immunology Letters</i> , 2019, 205, 1-8.	1.1	11
447	Investigation of the Skin Anti-photoaging Potential of Swertia chirayita Secoiridoids Through the AP-1/Matrix Metalloproteinase Pathway by Molecular Modeling. <i>International Journal of Peptide Research and Therapeutics</i> , 2019, 25, 517-533.	0.9	7
448	Multimodal Molecular Imaging Demonstrates Myeloperoxidase Regulation of Matrix Metalloproteinase Activity in Neuroinflammation. <i>Molecular Neurobiology</i> , 2019, 56, 954-962.	1.9	8
449	Matrix metalloproteinases sensitive multifunctional micelles for inhibition of metastatic tumor growth and metastasis. <i>Powder Technology</i> , 2019, 358, 3-12.	2.1	3
450	Matrix Metalloproteinase in Abdominal Aortic Aneurysm and Aortic Dissection. <i>Pharmaceuticals</i> , 2019, 12, 118.	1.7	106
451	Matrix Metalloproteases as Influencers of the Cells' Social Media. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3847.	1.8	62
452	Does Arterial Hypertension Affect Plasma Levels of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Stable Coronary Artery Disease? A Preliminary Study. <i>Cardiology Research and Practice</i> , 2019, 2019, 1-8.	0.5	6
453	The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma. <i>Cells</i> , 2019, 8, 984.	1.8	201
454	Metalloproteinases mediate diabetes-induced retinal neuropathy and vasculopathy. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 3157-3166.	2.4	36
455	Matrix metalloproteinases in the CNS: interferons get nervous. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 3083-3095.	2.4	36
456	Matrix metalloproteinases and inhibitors in dentistry. <i>Clinical Oral Investigations</i> , 2019, 23, 2823-2835.	1.4	51
457	Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition. <i>Journal of Biological Chemistry</i> , 2019, 294, 9476-9488.	1.6	25
458	STRIP2 silencing inhibits vascular smooth muscle cell proliferation and migration via P38/AKT/MMP signaling pathway. <i>Journal of Cellular Physiology</i> , 2019, 234, 22463-22476.	2.0	15
459	Novel Approaches for Extracellular Matrix Targeting in Disease Treatment. <i>Methods in Molecular Biology</i> , 2019, 1952, 261-275.	0.4	9

#	ARTICLE	IF	CITATIONS
460	Upregulated MMP28 in Hepatocellular Carcinoma Promotes Metastasis via Notch3 Signaling and Predicts Unfavorable Prognosis. <i>International Journal of Biological Sciences</i> , 2019, 15, 812-825.	2.6	15
461	Cellular and Molecular Effects of High-Molecular-Weight Heparin on Matrix Metalloproteinase 9 Expression. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1595.	1.8	3
462	Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3878-3887.	1.6	22
463	Intensity-modulated nanoplasmonic interferometric sensor for MMP-9 detection. <i>Lab on A Chip</i> , 2019, 19, 1267-1276.	3.1	13
464	Recent insights into natural product inhibitors of matrix metalloproteinases. <i>MedChemComm</i> , 2019, 10, 2024-2037.	3.5	15
466	Matrix Metalloproteinase Triple-Helical Peptide Inhibitors: Potential Cross-Reactivity with Caspase-11. <i>Molecules</i> , 2019, 24, 4355.	1.7	2
467	Effects of IL-1 β on MMP-9 Expression in Cementoblast-Derived Cell Line and MMP-Mediated Degradation of Type I Collagen. <i>Inflammation</i> , 2019, 42, 413-425.	1.7	23
468	Labeled and non-label electrochemical peptide inhibitor-based biosensing platform for determination of hemopexin domain of matrix metalloproteinase-14. <i>Talanta</i> , 2019, 194, 548-553.	2.9	12
469	Development of an inflammatory tissue-selective chimeric TNF receptor. <i>Cytokine</i> , 2019, 113, 340-346.	1.4	6
470	Propeptide glycosylation and galectin-3 binding decrease proteolytic activation of human pro-MMP-9/progelatinase B. <i>FEBS Journal</i> , 2019, 286, 930-945.	2.2	7
471	Developing an Antibody-Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein. <i>ChemBioChem</i> , 2019, 20, 754-758.	1.3	11
472	Matrix Metalloproteinases: A challenging paradigm of cancer management. <i>Seminars in Cancer Biology</i> , 2019, 56, 100-115.	4.3	169
473	The gelatinases, MMP-2 and MMP-9, as fine tuners of neuroinflammatory processes. <i>Matrix Biology</i> , 2019, 75-76, 102-113.	1.5	108
474	Monoclonal antibodies against metzincin targets. <i>British Journal of Pharmacology</i> , 2019, 176, 52-66.	2.7	38
476	Understanding the variability of the S1 β pocket to improve matrix metalloproteinase inhibitor selectivity profiles. <i>Drug Discovery Today</i> , 2020, 25, 38-57.	3.2	41
477	Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 756-763.	0.9	21
478	PCSK6 Is a Key Protease in the Control of Smooth Muscle Cell Function in Vascular Remodeling. <i>Circulation Research</i> , 2020, 126, 571-585.	2.0	38
479	Lipopolysaccharide-Induced Matrix Metalloproteinase-9 Expression Associated with Cell Migration in Rat Brain Astrocytes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 259.	1.8	21

#	ARTICLE	IF	CITATIONS
480	Icariside II improves myocardial fibrosis in spontaneously hypertensive rats by inhibiting collagen synthesis. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 227-235.	1.2	13
481	Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115257.	1.4	10
482	Naturally-occurring bacterial cellulose-hyperbranched cationic polysaccharide derivative/MMP-9 siRNA composite dressing for wound healing enhancement in diabetic rats. <i>Acta Biomaterialia</i> , 2020, 102, 298-314.	4.1	48
483	Drug delivery and tissue engineering applications of chitosan-based biomaterial systems. , 2020, , 555-588.		0
484	Hydroxamate-Based Selective Macrophage Elastase (MMP-12) Inhibitors and Radiotracers for Molecular Imaging. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15037-15049.	2.9	12
485	<p>Galangin Inhibits LPS-Induced MMP-9 Expression via Suppressing Protein Kinase-Dependent AP-1 and FoxO1 Activation in Rat Brain Astrocytes</p>. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 945-960.	1.6	23
486	A Complete and Versatile Protocol: Decoration of Cell-Derived Matrices with Mass-Encoded Peptides for Multiplexed Protease Activity Detection. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 6598-6617.	2.6	2
487	Developments in Carbohydrate-Based Metzincin Inhibitors. <i>Pharmaceuticals</i> , 2020, 13, 376.	1.7	4
488	Comparison of two ASC-derived therapeutics in an in vitro OA model: secretome versus extracellular vesicles. <i>Stem Cell Research and Therapy</i> , 2020, 11, 521.	2.4	30
489	Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11100-11120.	2.9	13
490	Epithelial cellâ€“specific loss of function of <i>Miz1</i> causes a spontaneous COPD-like phenotype and up-regulates <i>Ace2</i> expression in mice. <i>Science Advances</i> , 2020, 6, eabb7238.	4.7	16
491	Central Nervous System Targets: Glial Cell Mechanisms in Chronic Pain. <i>Neurotherapeutics</i> , 2020, 17, 846-860.	2.1	138
492	Challenges in Matrix Metalloproteinases Inhibition. <i>Biomolecules</i> , 2020, 10, 717.	1.8	43
493	Validating the 1,2-Difluoro Motif As a Hybrid Bioisostere of CF3 and Et Using Matrix Metalloproteinases As Structural Probes. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6225-6237.	2.9	15
494	Novel Barbiturate-Nitrate Compounds Inhibit the Upregulation of Matrix Metalloproteinase-9 Gene Expression in Intestinal Inflammation through a cGMP-Mediated Pathway. <i>Biomolecules</i> , 2020, 10, 808.	1.8	6
495	Collagen/GAG scaffolds activated by RALA-siMMP-9 complexes with potential for improved diabetic foot ulcer healing. <i>Materials Science and Engineering C</i> , 2020, 114, 111022.	3.8	20
496	Design, synthesis, and biological evaluation of 4-phenoxybenzenesulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. <i>BioScience Trends</i> , 2020, 14, 192-199.	1.1	4
497	Expression of MMP-2, MMP-9, and NGAL in Tissue and Serum of Patients with Vascular Aneurysms and Their Modulation by Statin Treatment: A Pilot Study. <i>Biomolecules</i> , 2020, 10, 359.	1.8	14

#	ARTICLE	IF	CITATIONS
498	Bivalent Inhibitor with Selectivity for Trimeric MMP-9 Amplifies Neutrophil Chemotaxis and Enables Functional Studies on MMP-9 Proteoforms. <i>Cells</i> , 2020, 9, 1634.	1.8	11
499	Redox-Neutral P(O)â€“N Coupling between P(O)â€“H Compounds and Azides via Dual Copper and Photoredox Catalysis. <i>Organic Letters</i> , 2020, 22, 6143-6149.	2.4	27
500	The Interplay Between Genetic Risk Factors and Proteolytic Dysregulation in the Pathophysiology of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1149-1161.	0.6	18
501	Collagen-Immobilized Extracellular FRET Reporter for Visualizing Protease Activity Secreted by Living Cells. <i>ACS Sensors</i> , 2020, 5, 655-664.	4.0	14
502	Abiotic Mimic of Endogenous Tissue Inhibitors of Metalloproteinases: Engineering Synthetic Polymer Nanoparticles for Use as a Broad-Spectrum Metalloproteinase Inhibitor. <i>Journal of the American Chemical Society</i> , 2020, 142, 2338-2345.	6.6	23
503	Collagenases and gelatinases and their inhibitors as anticancer agents. , 2020, , 265-294.		6
504	Remnant Epitopes Generating Autoimmunity: From Model to Useful Paradigm. <i>Trends in Immunology</i> , 2020, 41, 367-378.	2.9	28
505	Protease propeptide structures, mechanisms of activation, and functions. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2020, 55, 111-165.	2.3	37
506	Cardiac remodeling secondary to chronic volume overload is attenuated by a novel MMP9/2 blocking antibody. <i>PLoS ONE</i> , 2020, 15, e0231202.	1.1	6
507	Label-Free Quantitative Proteomics and Substrate-Based Mass Spectrometry Imaging of Xenobiotic Metabolizing Enzymes in Ex Vivo Human Skin and a Human Living Skin Equivalent Model. <i>Drug Metabolism and Disposition</i> , 2021, 49, 39-52.	1.7	12
508	Heroin Seeking and Extinction From Seeking Activate Matrix Metalloproteinases at Synapses on Distinct Subpopulations of Accumbens Cells. <i>Biological Psychiatry</i> , 2021, 89, 947-958.	0.7	26
509	Outline of gelatinase inhibitors as anti-cancer agents: A patent mini-review for 2010-present. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113044.	2.6	13
510	Tissue Inhibitor of Metalloproteinase (TIMP) Peptidomimetic as an Adjunctive Therapy for Infectious Keratitis. <i>Biomacromolecules</i> , 2021, 22, 629-639.	2.6	6
511	First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2021, 41, 65-76.	1.1	3
512	Challenges with matrix metalloproteinase inhibition and future drug discovery avenues. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 75-88.	2.5	15
513	Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils. <i>British Journal of Dermatology</i> , 2021, 184, 1004-1013.	1.4	15
514	Enzymes Matrix Metalloproteinases. , 2021, , 336-353.		1
515	Mechanisms of lower extremity vein dysfunction in chronic venous disease and implications in management of varicose veins. , 2021, 5, .		12

#	ARTICLE	IF	CITATIONS
516	Multi-organ damage by covid-19: congestive (cardio-pulmonary) heart failure, and blood-heart barrier leakage. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1891-1895.	1.4	17
517	Multifunctional intracellular matrix metalloproteinases: implications in disease. <i>FEBS Journal</i> , 2021, 288, 7162-7182.	2.2	146
518	Investigation of association of genetic variant rs3918242 of matrix metalloproteinase-9 with hypertension, myocardial infarction and progression of ventricular dysfunction in Irish Caucasian patients with diabetes: a report from the STOP-HF follow-up programme. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 87.	0.7	8
519	Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020). <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 509-523.	2.4	18
520	The Role of Extracellular Matrix Components in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 1122.	1.0	39
521	Analysis of the Effect of Blood Sugar, Calcium, Chloride Ions, and Blood Urea Nitrogen on Skin Wrinkles. <i>Asian Journal of Beauty and Cosmetology</i> , 2021, 19, 77-88.	0.2	1
522	Polymerizable Matrix Metalloproteinases™ Inhibitors with Potential Application for Dental Restorations. <i>Biomedicines</i> , 2021, 9, 366.	1.4	2
523	Inflammatory Regulation by TNF- α -Activated Adipose-Derived Stem Cells in the Human Bladder Cancer Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3987.	1.8	13
525	Respiratory syncytial virus induces β_2 -adrenergic receptor dysfunction in human airway smooth muscle cells. <i>Science Signaling</i> , 2021, 14, .	1.6	6
526	Relationships Between Perivascular Adipose Tissue and Abdominal Aortic Aneurysms. <i>Frontiers in Endocrinology</i> , 2021, 12, 704845.	1.5	15
527	Selective Imaging of Matrix Metalloproteinase-13 to Detect Extracellular Matrix Remodeling in Atherosclerotic Lesions. <i>Molecular Imaging and Biology</i> , 2021, , 1.	1.3	5
528	Design, Synthesis, and Utility of Defined Molecular Scaffolds. <i>Organics</i> , 2021, 2, 161-273.	0.6	14
529	Elevated Plasma Levels of Matrix Metalloproteinase-3 and Tissue-Inhibitor of Matrix Metalloproteinases-1 Associate With Organ Dysfunction and Mortality in Sepsis. <i>Shock</i> , 2022, 57, 41-47.	1.0	14
530	Identification of Broad-Spectrum MMP Inhibitors by Virtual Screening. <i>Molecules</i> , 2021, 26, 4553.	1.7	6
531	Chronic Cadmium Exposure Alters Cardiac Matrix Metalloproteinases in the Heart of Sprague-Dawley Rat. <i>Frontiers in Pharmacology</i> , 2021, 12, 663048.	1.6	14
532	Molecular Interactions of Arterial Hypertension in Its Target Organs. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9669.	1.8	11
533	Clinical and Pathological Correlations in Chronic Venous Disease. <i>Annals of Vascular Surgery</i> , 2022, 78, 19-27.	0.4	6
534	Roles of matrix metalloproteinases in the cornea: A special focus on macular corneal dystrophy. <i>Medicine in Drug Discovery</i> , 2021, 11, 100095.	2.3	6

#	ARTICLE	IF	CITATIONS
535	Targeting cancer-associated fibroblasts in immunotherapy. , 2022, , 163-209.		2
536	Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives. International Journal of Molecular Sciences, 2021, 22, 1413.	1.8	76
538	In Vitro and In Vivo Models of Angiogenesis to Dissect MMP Functions. , 2008, , 305-325.		5
539	Assessment of Synthetic Matrix Metalloproteinase Inhibitors by Fluorogenic Substrate Assay. Methods in Molecular Biology, 2016, 1406, 161-170.	0.4	3
540	Advances in Studies on Collagenase Inhibitors. Exs, 2012, 103, 83-135.	1.4	4
541	The Role of Matrix Metalloproteinases in Cellular Invasion and Metastasis. , 2011, , 145-191.		5
543	Nanofiber composites in vascular tissue engineering. , 2017, , 455-481.		13
544	Type-1 cytokines regulate matrix metalloprotease-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. JCI Insight, 2020, 5, .	2.3	31
545	Broad-Spectrum Matrix Metalloproteinase Inhibition Curbs Inflammation and Liver Injury but Aggravates Experimental Liver Fibrosis in Mice. PLoS ONE, 2010, 5, e11256.	1.1	55
546	Insufficiently Defined Genetic Background Confounds Phenotypes in Transgenic Studies As Exemplified by Malaria Infection in Tlr9 Knockout Mice. PLoS ONE, 2011, 6, e27131.	1.1	16
547	Hepatoprotective Effect of MMP-19 Deficiency in a Mouse Model of Chronic Liver Fibrosis. PLoS ONE, 2012, 7, e46271.	1.1	25
548	Increased Matrix Metalloproteinase (MMPs) Levels Do Not Predict Disease Severity or Progression in Emphysema. PLoS ONE, 2013, 8, e56352.	1.1	43
549	Relationship between Vitreous Levels of Matrix Metalloproteinases and Vascular Endothelial Growth Factor in Proliferative Diabetic Retinopathy. PLoS ONE, 2013, 8, e85857.	1.1	70
550	Inhibitory Effect of Aqueous Extracts from Marine Sponges on the Activity and Expression of Gelatinases A (MMP-2) and B (MMP-9) in Rat Astrocyte Cultures. PLoS ONE, 2015, 10, e0129322.	1.1	13
551	Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Aqueous Humor of Diabetic Macular Edema Patients. PLoS ONE, 2016, 11, e0159720.	1.1	33
552	Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. PLoS ONE, 2017, 12, e0174853.	1.1	35
553	Stem cell and cancer stem cell games on the ECM field. Journal of Cancer Stem Cell Research, 2013, 1, 1.	1.1	5
554	Ganoderma lucidum, a promising agent possessing antioxidant and anti-inflammatory effects for treating calvarial defects with graft application in rats. Acta Cirurgica Brasileira, 2019, 34, e201900904.	0.3	9

#	ARTICLE	IF	CITATIONS
555	Minocycline is More Potent Than Tetracycline and Doxycycline in Inhibiting MMP-9 in Vitro. Jundishapur Journal of Natural Pharmaceutical Products, 2016, 11, .	0.3	11
556	Role of DDX3 in the pathogenesis of inflammatory bowel disease. Oncotarget, 2017, 8, 115280-115289.	0.8	9
557	Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity. Oncotarget, 2012, 3, 1236-1245.	0.8	13
558	Probes for Non-invasive Matrix Metalloproteinase-targeted Imaging with PET and SPECT. Current Pharmaceutical Design, 2013, 19, 4647-4672.	0.9	65
559	Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases. Current Pharmaceutical Design, 2014, 20, 2993-3018.	0.9	22
560	Matrix Metalloproteinases: Drug Targets for Myocardial Infarction. Current Drug Targets, 2013, 14, 276-286.	1.0	31
561	Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase-7. Current Topics in Medicinal Chemistry, 2020, 20, 2459-2471.	1.0	6
562	Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets. CNS and Neurological Disorders - Drug Targets, 2014, 13, 63-81.	0.8	20
563	Current and novel radiopharmaceuticals for imaging cardiovascular inflammation. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 4-20.	0.4	10
565	Zinc-Containing Metalloenzymes: Inhibition by Metal-Based Anticancer Agents. Frontiers in Chemistry, 2020, 8, 402.	1.8	29
566	Matrix Metalloproteinases, New Insights into the Understanding of Neurodegenerative Disorders. Biomolecules and Therapeutics, 2012, 20, 133-143.	1.1	79
567	A quitosana como biomaterial odontolÃ³gico: estado da arte. Revista Brasileira De Engenharia Biomedica, 2013, 29, 110-120.	0.3	21
568	Gelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain. World Journal of Biological Chemistry, 2011, 2, 14.	1.7	56
569	Abalone Haliotis discus hannai Intestine Digests with Different Molecule Weights Inhibit MMP-2 and MMP-9 Expression in Human Fibrosarcoma Cells. Fisheries and Aquatic Sciences, 2012, 15, 137-143.	0.3	4
570	When phosphoryl azide meets mechanochemistry: clean, rapid, and efficient synthesis of phosphoryl amides under B(C ₆ F ₅) ₃ catalysis in a ball mill. Catalysis Science and Technology, 2021, 11, 6659-6665.	2.1	4
571	ECM-LSE: Prediction of Extracellular Matrix Proteins Using Deep Latent Space Encoding of k-Spaced Amino Acid Pairs. Frontiers in Bioengineering and Biotechnology, 2021, 9, 752658.	2.0	6
572	A functional polymorphism at the miR-491-5p binding site in the 3' untranslated region of the MMP-9 gene increases the risk of developing ventilator-associated pneumonia. International Journal of Molecular Medicine, 2021, 48, .	1.8	4
573	Ligand-based design of anticancer MMP2 inhibitors: a review. Future Medicinal Chemistry, 2021, 13, 1987-2013.	1.1	9

#	ARTICLE	IF	CITATIONS
574	Inhibitoren von hydrolytisch spaltenden Metalloenzymen. , 2009, , 403-425.		0
575	Neurobiology of Postischemic Recuperation in the Aged Mammalian Brain. , 2009, , 403-451.		0
577	Cases for 3D Cultures in Drug Discovery. , 2010, , 289-305.		0
578	Matrix Metalloproteinase Inhibitors as New Anti-inflammatory Drugs. , 2011, , 101-122.		0
581	Intracellular Matrix Remodeling and Cardiac Function in Ischemiaâ€“Reperfusion Injury. , 2013, , 467-485.		0
582	Implications of Intracellular Proteolytic Activation of MMP-2 in the Heart. , 2014, , 335-349.		0
583	Targeting Matrix Metalloproteinase 2 and 9 for Treatment of Cardiovascular Dysfunction of Diabetes. , 2014, , 359-375.		0
584	Biomarkers of Extracellular Matrix Remodeling in Liver Diseases. Exposure and Health, 2015, , 1-26.	2.8	0
585	Matrix Metalloproteinases. , 2016, , 1-9.		0
586	Matrix Metalloproteinases in Asthma-Associated Airway Remodeling â€“ Dr. Jekyll or Mr. Hyde ?. , 0, , .		2
587	Role of Proteases in Breast Cancer. , 2017, , 3-22.		0
588	Gastric Pathology and Metalloproteinases. , 2017, , 489-513.		0
589	Proteases in Neuropathophysiology. , 2017, , 131-145.		0
590	Biomarkers of Extracellular Matrix Remodeling in Liver Diseases. Biomarkers in Disease, 2017, , 221-246.	0.0	3
591	Natural Polyphenols as Prospective Inhibitors for MMPs Remodeling in Human Diseases. , 2017, , 263-283.		0
593	Diyabetik Ayak YaralarÄ± Ä°mmonohistokimyasal Bir Ä±alÄ±ÄŸma; MMP-2 ve TNF- Î± EkspresyonlarÄ±nÄ±n Ä°ncelenmesi. Harran Ä°niversitesi TÄ±p FakÄ°ltesi Dergisi, 0, , .	0.1	0
594	Discovery of potent and specific inhibitors targeting the active site of MMP-9 from the engineered SPINK2 library. PLoS ONE, 2020, 15, e0244656.	1.1	5
595	Role of Matrix Metalloproteinases in Colorectal Cancer. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 49-59.	0.2	2

#	ARTICLE	IF	CITATIONS
596	Substitution of diarylphosphoryl azides with aliphatic amines catalyzed by simple rare-earth metal salts: Efficient and novel preparation of phosphoryl amides. <i>Applied Organometallic Chemistry</i> , 2022, 36, e6507.	1.7	1
597	Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 54-60.	1.2	11
598	Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. <i>American Journal of Translational Research (discontinued)</i> , 2011, 3, 149-58.	0.0	36
599	Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer. <i>International Journal of Clinical and Experimental Medicine</i> , 2011, 4, 265-75.	1.3	32
600	Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. <i>Current Drug Targets</i> , 2013, 14, 287-324.	1.0	59
601	Matrix metalloproteinases: drug targets for myocardial infarction. <i>Current Drug Targets</i> , 2013, 14, 276-86.	1.0	34
602	Effect of cold ischemia/reperfusion injury and/or shear stress with portal hypertension on the expression of matrix metalloproteinase-9. <i>Annals of Gastroenterology</i> , 2012, 25, 345-351.	0.4	4
603	Altered serum level of cartilage oligomeric matrix protein and its association with coronary calcification in patients with coronary heart disease. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 87-92.	0.2	6
604	Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments. <i>Future Medicinal Chemistry</i> , 2022, 14, 35-51.	1.1	3
605	Proteoform Analysis of Matrix Metalloproteinase-9/Gelatinase B and Discovery of Its Citrullination in Rheumatoid Arthritis Synovial Fluids. <i>Frontiers in Immunology</i> , 2021, 12, 763832.	2.2	7
606	Synthetic Studies toward the Berkeleyacetal Core Architecture. <i>Organic Letters</i> , 2021, 23, 9227-9231.	2.4	8
607	Chondroprotective effects of CDK4/6 inhibition via enhanced ubiquitin-dependent degradation of JUN in synovial fibroblasts. <i>Rheumatology</i> , 2022, 61, 3427-3438.	0.9	7
608	Study of metalloproteinases in the blood of goats experimentally infected with caprine encephalitis arthritis virus. <i>Semina:Ciencias Agrarias</i> , 2020, 41, 3165-3176.	0.1	0
609	Effect of high-intensity interval training on tissue changes of collagen type 1 and fibrosis percent in male rats with myocardial infarction. <i>Koomesh</i> , 2021, 23, 267-274.	0.1	0
610	Identifying simultaneous matrix metalloproteinases/soluble epoxide hydrolase inhibitors. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 877-884.	1.4	0
611	Biodegradable Fiducial Markers for Bimodal Near-Infrared Fluorescence- and X-ray-Based Imaging. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 859-870.	2.6	3
612	Engineering of tissue inhibitor of metalloproteinases TIMP-1 for fine discrimination between closely related stromelysins MMP-3 and MMP-10. <i>Journal of Biological Chemistry</i> , 2022, 298, 101654.	1.6	13
613	Extracellular vesicle and soluble fractions of adipose tissue-derived mesenchymal stem cells secretome induce inflammatory cytokines modulation in an in vitro model of discogenic pain. <i>Spine Journal</i> , 2022, 22, 1222-1234.	0.6	12

#	ARTICLE	IF	CITATIONS
614	Mechanism of Blood-Heart-Barrier Leakage: Implications for COVID-19 Induced Cardiovascular Injury. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13546.	1.8	9
615	Molecular design of near-infrared (NIR) fluorescent probes targeting exopeptidase and application for detection of dipeptidyl peptidase 4 (DPP-4) activity. <i>RSC Chemical Biology</i> , 2022, 3, 859-867.	2.0	5
616	A ratiometric fluorescent probe based on peptide modified MnFe ₂ O ₄ nanoparticles for matrix metalloproteinase-7 activity detection <i>in vitro</i> and <i>in vivo</i> . <i>Analyst</i> , 2022, 147, 1581-1588.	1.7	6
617	Protein Synthesis/Degradation: Protein Degradation – Protease Classes Matrix Metalloproteinases. , 2022, , .		0
618	A motif in metalloproteinase inhibitor decreases effectively the activity of macrophage metalloproteinases. <i>Current Proteomics</i> , 2022, 19, .	0.1	0
619	Chronic infusion of ELABELA alleviates vascular remodeling in spontaneously hypertensive rats via anti-inflammatory, anti-oxidative and anti-proliferative effects. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2573-2584.	2.8	13
620	Role of matrix metalloproteinases in mitral valve regurgitation: Association between the of MMP ¹ , MMP ⁹ , TIMP ¹ , and TIMP ² expression, degree of mitral valve insufficiency, and pathologic etiology. <i>Journal of Cardiac Surgery</i> , 2022, , .	0.3	5
621	Berberine regulates bone metabolism in apical periodontitis by remodelling the extracellular matrix. <i>Oral Diseases</i> , 2021, , .	1.5	0
622	Comprehensive analysis of matrix metalloproteinases and their inhibitors in head and neck squamous cell carcinoma. <i>Acta Oncologica</i> , 2022, 61, 505-515.	0.8	5
623	Bioorthogonal in situ assembly of nanomedicines as drug depots for extracellular drug delivery. <i>Nature Communications</i> , 2022, 13, 2038.	5.8	27
624	Copper-Catalyzed Phosphorylation of <i>N,N</i> -Disubstituted Hydrazines: Synthesis of Multisubstituted Phosphorylhydrazides as Potential Anticancer Agents. <i>Journal of Organic Chemistry</i> , 2022, 87, 6224-6236.	1.7	11
628	Human Wharton's Jelly Mesenchymal Stem Cells Secretome Inhibits Human SARS-CoV-2 and Avian Infectious Bronchitis Coronaviruses. <i>Cells</i> , 2022, 11, 1408.	1.8	6
629	Interval-Based Secretomics Unravels Acute-Phase Response in Hepatocyte Model Systems. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100241.	2.5	2
630	Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology. <i>Pharmacological Reviews</i> , 2022, 74, 714-770.	7.1	95
631	Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8493-8510.	2.9	9
632	Human Malignant Rhabdoid Tumor Antigens as Biomarkers and Potential Therapeutic Targets. <i>Cancers</i> , 2022, 14, 3685.	1.7	5
633	Selective Inhibitors of Medium-Size S1 ² Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 10709-10754.	2.9	13
634	Blue LED-Mediated Syntheses of Arylazo Phosphine Oxides and Phosphonates via N-P Bond Formation. <i>Organic Letters</i> , 2022, 24, 5988-5993.	2.4	3

#	ARTICLE	IF	CITATIONS
635	Electrogenerated chemiluminescence biosensor for assay of matrix metalloproteinase-14 and protein-expressing cancer cells via inhibitory peptides-based sandwich assay. <i>Microchemical Journal</i> , 2022, 181, 107829.	2.3	1
636	Hydroxypyron derivatives in drug discovery: from chelation therapy to rational design of metalloenzyme inhibitors. <i>RSC Medicinal Chemistry</i> , 2022, 13, 1127-1149.	1.7	4
638	Protective role of <i>Caesalpinia sappan</i> extract and its main component brazilin against blue light-induced damage in human fibroblasts. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 7025-7034.	0.8	2
639	Chloride Intracellular Channel Proteins (CLICs) and Malignant Tumor Progression: A Focus on the Preventive Role of CLIC2 in Invasion and Metastasis. <i>Cancers</i> , 2022, 14, 4890.	1.7	5
640	Revealing immune infiltrate characteristics and potential diagnostic value of immune-related genes in ulcerative colitis: An integrative genomic analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
641	Design, synthesis, and biological evaluation of new heterocycles bearing both silicon and phosphorus as potent MMP-2 inhibitors. <i>Journal of the Chinese Chemical Society</i> , 2022, 69, 1908-1923.	0.8	4
642	Efficiency and Safety of Dextran-PAMAM/siMMP-9 Complexes for Decreasing Matrix Metalloproteinase-9 Expression and Promoting Wound Healing in Diabetic Rats. <i>Bioconjugate Chemistry</i> , 2022, 33, 2398-2410.	1.8	2
644	Peptide Vaccine Against ADAMTS-7 Ameliorates Atherosclerosis and Postinjury Neointima Hyperplasia. <i>Circulation</i> , 2023, 147, 728-742.	1.6	14
645	Molecular Basis of Intestinal Fibrosis in Inflammatory Bowel Disease. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 119-127.	0.8	3
646	Discovery of TP0597850: A Selective, Chemically Stable, and Slow Tight-Binding Matrix Metalloproteinase-2 Inhibitor with a Phenylbenzamide-Pentapeptide Hybrid Scaffold. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 822-836.	2.9	4
647	Quantum Dot-Peptide Conjugates as Energy Transfer Probes for Sensing the Proteolytic Activity of Matrix Metalloproteinase-14. <i>Analytical Chemistry</i> , 2023, 95, 2713-2722.	3.2	10
648	Characterization of Active MMP9 in Chronic Inflammatory Diseases Using a Novel Anti-MMP9 Antibody. <i>Antibodies</i> , 2023, 12, 9.	1.2	1
649	Isolation and Characterization of Protease Inhibitors with Antimicrobial Activity from <i>Sirisa</i> (<i>Albizia</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.2	0
651	Identification of potential biomarkers and therapeutic targets for posttraumatic acute respiratory distress syndrome. <i>BMC Medical Genomics</i> , 2023, 16, .	0.7	0
652	Inflachromene inhibits intimal hyperplasia through the HMGB1/2- regulated TLR4-NF- κ B pathway. <i>International Immunopharmacology</i> , 2023, 119, 110198.	1.7	2
653	Matrix metalloproteinases in arthritis: towards precision medicine. <i>Nature Reviews Rheumatology</i> , 2023, 19, 363-377.	3.5	20
660	Matrix Metalloproteinase-9 and Its Involvement in Parkinson's Disease. <i>Neurochemical Journal</i> , 2023, 17, 236-242.	0.2	0
666	The roles of intracellular proteolysis in cardiac ischemia-reperfusion injury. <i>Basic Research in Cardiology</i> , 2023, 118, .	2.5	3

#	ARTICLE	IF	CITATIONS
669	Antibody drug conjugates beyond cytotoxic payloads. Progress in Medicinal Chemistry, 2023, , 1-59.	4.1	0
679	Inhibitoren von hydrolytisch spaltenden Metalloenzymen., 2023, , 477-504.		0